var title_f29_47_30448="Typical granuloma of Crohns disease";
var content_f29_47_30448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical granuloma of Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 119px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrographs showing granulomatous lesion that is diagnostic of Crohn's disease. Low and high power views show a central giant cell surrounded by epitheliod cells and rimmed by lymphocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30448=[""].join("\n");
var outline_f29_47_30448=null;
var title_f29_47_30449="Loculated pneumothorax CT";
var content_f29_47_30449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of a loculated pneumothorax in a patient with AIDS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows multiple pockets of loculated gas in the right hemithorax due to multiple adhesions from previous recurring bouts of pneumothorax. A small loculated effusion is seen in the right major fissure and simulates a solitary pulmonary nodule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30449=[""].join("\n");
var outline_f29_47_30449=null;
var title_f29_47_30450="Patient information: Polymyositis (The Basics)";
var content_f29_47_30450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/63/5106\">",
"         Patient information: Dermatomyositis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/11/26804\">",
"         Patient information: Myositis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Polymyositis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/polymyositis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H20048703\">",
"      <span class=\"h1\">",
"       What is polymyositis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Polymyositis (PM) is a condition that causes muscle weakness. In PM, the muscles get inflamed. Doctors don&rsquo;t know what causes PM.",
"     </p>",
"     <p>",
"      PM is more common in adults, but it can also happen in children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20048718\">",
"      <span class=\"h1\">",
"       What are the symptoms of polymyositis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PM causes muscle weakness. The weakness affects both sides of the body and usually happens slowly over time. It involves muscles closest to the trunk of the body, such as those in the neck, shoulders, hips, and thighs. Depending on the muscles involved, people with PM can have trouble climbing stairs, lifting things above their head, or swallowing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20048733\">",
"      <span class=\"h1\">",
"       Is there a test for polymyositis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will order 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Electromyography, or &ldquo;EMG&rdquo; &ndash; This test shows whether your muscles are responding to the nerves&rsquo; electrical signals in the correct way.",
"       </li>",
"       <li>",
"        Muscle biopsy &ndash; For this test, the doctor takes a small sample of tissue from a muscle that is weak. Then another doctor looks at the sample under a microscope.",
"       </li>",
"       <li>",
"        An imaging test called an MRI scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20048748\">",
"      <span class=\"h1\">",
"       How is polymyositis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for PM includes medicines called steroids. Steroids help reduce inflammation. These steroids are different from the ones athletes take to build muscle.",
"     </p>",
"     <p>",
"      People with PM usually need to take steroids for a long time. But steroids have side effects of their own. They can make your bones weak and raise your chances of getting an infection. To avoid these side effects as much as possible, your doctor will slowly lower (or &ldquo;taper&rdquo;) your dose over time.",
"     </p>",
"     <p>",
"      If you can&rsquo;t take steroids, the steroids don&rsquo;t help enough, or your symptoms come back, your doctor can treat you with other medicines. These medicines help reduce inflammation, too, but are different than steroids. Sometimes, doctors prescribe both steroids and these other medicines at the same time to treat PM.",
"     </p>",
"     <p>",
"      Other treatment for PM involves keeping your body as strong as possible and preventing further problems. This usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Working with a physical therapist (exercise expert) to learn exercises to strengthen your muscles",
"       </li>",
"       <li>",
"        Changing what and how you eat, if you have trouble swallowing or choke easily on your food",
"       </li>",
"       <li>",
"        Taking medicines to help prevent side effects from the steroids",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20048763\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. He or she will work with you to get your PM under control before you try to get pregnant. Plus, he or she will make sure your medicines are safe to take during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20048778\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your individual situation. Some people with PM have only mild symptoms. But many people have more bothersome symptoms that last years.",
"     </p>",
"     <p>",
"      PM can also cause other types of long-term medical problems. These include lung and heart problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20048793\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=see_link\">",
"       Patient information: Dermatomyositis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       Patient information: Myositis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/47/30450?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83085 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30450=[""].join("\n");
var outline_f29_47_30450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048703\">",
"      What is polymyositis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048718\">",
"      What are the symptoms of polymyositis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048733\">",
"      Is there a test for polymyositis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048748\">",
"      How is polymyositis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048763\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048778\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20048793\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=related_link\">",
"      Patient information: Dermatomyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_47_30451="Gastric cancer Endosc";
var content_f29_47_30451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic appearances of gastric cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows different appearances of a gastric adenocarcinoma. Upper panel: Adenocarcinoma in the antrum manifested by a friable, ulcerated, and circumferential mass. Lower panel: Adenocarcinoma of the cardia. This large, lobulated, ulcerated mass was seen only by retroflexed views of the gastroesophageal junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30451=[""].join("\n");
var outline_f29_47_30451=null;
var title_f29_47_30452="m-Cresyl acetate: Patient drug information";
var content_f29_47_30452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   m-Cresyl acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/14/9442?source=see_link\">",
"     see \"m-Cresyl acetate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cresylate&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to m-cresyl acetate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a ruptured ear drum.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear discomfort.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12074 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30452=[""].join("\n");
var outline_f29_47_30452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191412\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013755\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013754\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013759\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013760\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013762\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013757\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013758\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013763\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013764\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/14/9442?source=related_link\">",
"      m-Cresyl acetate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_47_30453="Femoral hernia repair";
var content_f29_47_30453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Femoral hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The&nbsp;placement of mesh during&nbsp;femoral hernia repair is illustrated.&nbsp;The circular component of the mesh is placed&nbsp;in the preperitoneal space, and the oblong portion is placed between the external oblique and internal oblique muscles extending downward to the inguinal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30453=[""].join("\n");
var outline_f29_47_30453=null;
var title_f29_47_30454="Massive hemoptysis: Initial management";
var content_f29_47_30454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Massive hemoptysis: Initial management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30454/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30454/contributors\">",
"     David H Ingbar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30454/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30454/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30454/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30454/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/47/30454/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with massive hemoptysis, the initial steps are to correctly position the patient, establish a patent airway, insure adequate gas exchange and cardiovascular function, and control the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/1\">",
"     1",
"    </a>",
"    ]. These steps are reviewed here. Other aspects of massive hemoptysis (ie, definition, etiologies, diagnostic evaluation, and definitive treatment) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29558?source=see_link\">",
"     \"Overview of massive hemoptysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26838?source=see_link\">",
"     \"Massive hemoptysis: Causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4655275\">",
"    <span class=\"h1\">",
"     IDENTIFY WHICH SIDE IS BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in managing a patient with massive hemoptysis is to determine which lung is likely bleeding. This may be difficult. Occasionally, on the bleeding side there is a history of lung disease or there may be a gurgling sound that can be auscultated, or an abnormal sensation. However, many signs are misleading because they occur away from the bleeding site. As an example, upper lobe hemorrhage may manifest wheezing, rhonchi, or air space disease in the lower lobe, due to the accumulation of blood in the lower lobe with gravitational pooling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4655266\">",
"    <span class=\"h1\">",
"     POSITION THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with massive hemoptysis should be immediately placed into a position in which the presumed bleeding lung is in the dependent position. A patient whose right lung is bleeding should be placed in the right-side down decubitus position, whereas a patient whose left lung is bleeding should be placed in the left-side down decubitus position. The purpose of these positions is to protect the non-bleeding lung, since spillage of blood into the non-bleeding lung may prevent gas exchange by blocking the airway with clot or filling the alveoli with blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4655170\">",
"    <span class=\"h1\">",
"     ESTABLISH A PATENT AIRWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with massive hemoptysis who have severe shortness of breath, poor gas exchange, hemodynamic instability, or rapid ongoing hemoptysis, should be intubated with a large bore endotracheal tube (size 8.0 or greater, if possible). The purpose of the large size is to facilitate interventional and diagnostic bronchoscopy.",
"   </p>",
"   <p>",
"    When the bleeding is coming from one lung, it may be possible to protect the nonbleeding lung from spillage by using of one of the following techniques for intubation and mechanical ventilation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unilateral lung ventilation is performed by selectively inserting a typical, single lumen endotracheal tube into the mainstem bronchus of the non-bleeding lung. The goal is for the inflated cuff of the endotracheal tube to protect the nonbleeding lung from the spillage of blood. Thus, a patient whose right lung is bleeding should have his or her left mainstem bronchus intubated, whereas a patient whose left lung is bleeding should have his or her right mainstem bronchus intubated. A potential problem with right mainstem bronchial intubation is that the right upper lobe bronchus may become blocked. Unilateral lung ventilation is typically done in the setting of a localizing bronchoscopic exam, since it is essential that the bleeding lung be correctly identified. Unilateral lung ventilation may be combined with use of a bronchial blocker or balloon tamponade. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bronchoscopy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Double-lumen endotracheal tubes have two separate lumens of differing length [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/2\">",
"       2",
"      </a>",
"      ]. Generally, a left-sided double-lumen tube is preferred over the right-sided tube, as it is technically easier to insert and avoids possible obstruction of the right upper lobe bronchus when the bronchial balloon cuff is inflated. With the left-sided tube, the longer lumen terminates within the left main bronchus, while the shorter lumen terminates in the distal trachea. After insertion, the bronchial cuff is inflated within the left main bronchus to prevent blood or secretions from passing from one side to the other. A separate cuff is inflated within the trachea, just cephalad to the orifice of the shorter (tracheal) lumen. &nbsp;",
"      <br/>",
"      <br/>",
"      Ideally, correct placement is ascertained by bronchoscopy through the tracheal lumen, using a pediatric bronchoscope. The main carina dividing the right and left main bronchi should be visualized approximately 2 cm distal to the tracheal lumen orifice. The bronchial cuff should be about 5 mm distal to the main carina without herniation across the carina. When the bronchoscope is passed through the longer (bronchial) lumen, the carina between the left upper and lower bronchi should be visible. A chest x-ray is subsequently obtained to assess correct positioning by identifying the radio-opaque strip on the double-lumen tube.",
"      <br/>",
"      <br/>",
"      Mechanical ventilation using a double-lumen endotracheal tube permits ventilation of both lungs, while preventing the aspiration of blood from one lung to the other. However, the tubes are difficult to insert, especially when patients are bleeding rapidly. Even if the tube is successfully inserted, maintaining its proper position is difficult. Patients typically need to be paralyzed or not moved unless absolutely necessary because the tube easily may shift position if the patient moves, potentially leading to blood spillage or bronchial obstruction. In addition, each lumen is small, which predisposes the tube to becoming obstructed by clots. In addition, the small lumen does not allow passage of a bronchoscope with an effective suction channel and often necessitates changing to an endotracheal tube with a lumen large enough for diagnostic procedures. Due to these practical limitations, double-lumen endotracheal tubes are usually recommended only for patients who are exsanguinating",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asphyxiating from their bleeding and when no other approaches are possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4655178\">",
"    <span class=\"h1\">",
"     INSURE ADEQUATE GAS EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with massive hemoptysis may become hypoxemic, hypercapnic, or both. There are no unique ventilatory strategies for patients with massive hemoptysis. In our clinical practice, we generally deliver volume-targeted breaths using assist control ventilation. However, alternative modes of mechanical ventilation are also acceptable. An approach to establishing initial ventilator settings is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of mechanical ventilation\", section on 'Initiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4655222\">",
"    <span class=\"h1\">",
"     INSURE ADEQUATE CARDIOVASCULAR FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with massive hemoptysis are typically tachycardic and may become hypotensive. Such patients should be managed with volume resuscitation. Crystalloid intravenous fluids are generally administered first because they are readily available. However, blood products are an appropriate alternative in patients who are coagulopathic, anemic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding rapidly. Patients with massive hemoptysis may also have arrhythmias that are probably a consequence of respiratory distress and hypoxemia. Arrhythmias are best managed by optimizing gas exchange as described above and then using direct therapy if they persist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4655186\">",
"    <span class=\"h1\">",
"     CONTROL THE BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many strategies to control pulmonary hemorrhage. Such approaches may be categorized as non-surgical or surgical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7235390\">",
"    <span class=\"h2\">",
"     Non-surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-surgical approaches to controlling the bleeding include blood product infusion, bronchoscopy, and arteriography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7235375\">",
"    <span class=\"h3\">",
"     Blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with massive hemoptysis should have all known or suspected coagulation abnormalities rapidly reversed. Those who are receiving an anticoagulant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ) or have an elevated prothrombin time, partial thromboplastin time, or international normalized ratio should receive fresh frozen plasma. Those who are thrombocytopenic should receive a platelet transfusion. Patients who are uremic or taking an antiplatelet agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) may also benefit from transfused platelets. Finally, the administration of recombinant combination factor VIIa may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Pulmonary hemorrhage'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of bronchoscopic techniques that may control pulmonary hemorrhage. They include balloon tamponade, iced saline lavage, topical medications, laser therapy, and electrocautery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balloon tamponade &ndash; Balloon tamponade involves placement of a 4 Fr. 100 cm Fogarty balloon catheter or an alternative device (eg, the Arndt endobronchial blocker) into the segmental or subsegmental bronchus that leads to the bleeding site. The balloon is kept inflated for 24 to 48 hours and then deflated. Once the balloon is deflated, the patient is observed for rebleeding for several hours [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/3\">",
"       3",
"      </a>",
"      ]. If there is no evidence of rebleeding, the balloon catheter is removed. There are theoretical risks of ischemic mucosal injury and postobstructive pneumonia due to balloon tamponade, but these complications have not been reported.",
"     </li>",
"     <li>",
"      Iced saline lavage &ndash; To perform iced saline lavage, approximately 1L of saline (eg, twenty 50 mL syringes) should be cooled in ice while the above described goals (ie, patent airway, adequate gas exchange, and adequate cardiovascular function) are being achieved and the bronchoscopy equipment is being set up. Once the saline has cooled, bronchoscopy is performed and the source of bleeding is localized. The bleeding source is then lavaged using 50 mL aliquots of cold saline. In one case series, the average volume of saline used was 500 mL per patient [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/4\">",
"       4",
"      </a>",
"      ]. It is believed that iced saline lavage works by causing local vasoconstriction, reducing blood flow, and promoting hemostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/5\">",
"       5",
"      </a>",
"      ]. There are no controlled data showing benefit and we use this only very rarely.",
"     </li>",
"     <li>",
"      Topical medications &ndash; A topical vasoconstrictive agent (usually epinephrine [1:20,000] or vasopressin) or a topical coagulant (eg, thrombin or a fibrinogen-thrombin combination) can be infused through a bronchoscope and directly onto the bleeding source to slow or stop the bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/6\">",
"       6",
"      </a>",
"      ]. These methods have not been compared in trials; however, our clinical experience suggests that topical epinephrine is as effective as or more effective than the alternative topical medications.",
"     </li>",
"     <li>",
"      Laser therapy, electrocautery, argon plasma coagulation, or cryotherapy may be able to stop the bleeding if bronchoscopy identifies a bleeding mucosal lesion. These techniques can be implemented through a flexible or rigid bronchoscope; however, rigid bronchoscopy is preferable because it has better suction capability and excellent visualization of the bleeding lesion is required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=see_link\">",
"       \"Bronchoscopic laser resection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11447?source=see_link\">",
"       \"Endobronchial electrocautery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic aspects of bronchoscopy in massive hemoptysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29558?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of massive hemoptysis\", section on 'Bronchoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriographic embolization can localize potential bleeding sites and treat the bleeding by embolization. It is generally employed when there is persistent brisk hemoptysis despite bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Arteriographic embolization is performed in a radiological suite by an interventional or vascular radiologist. It can be performed in intubated, critically ill patients and, therefore, is useful for patients with a greater severity of illness.",
"   </p>",
"   <p>",
"    Arteriographic embolization involves focally injecting intravenous contrast material to define the intended arterial circulation (bronchial, pulmonary, or systemic), identifying the potential bleeding site, and then inserting occlusive material into either the bleeding vessel itself or the proximal vessels that supply the bleeding vessel. Routine post-embolization thoracic aortography is sometimes performed to improve the detection of bleeding from the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bronchial arteries should be the first vessels studied in most patients with massive hemoptysis because they are the most common source of bleeding. Bronchial arteriography has the following limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior spinal artery arises from a bronchial artery in approximately 5 percent of the population. As a result, cannulation or proximal embolization of the bronchial artery may block flow to the anterior spinal cord, resulting in paraplegia. Bronchial arteriography should only be performed by experienced operators because the risk of paraplegia is less than 1 percent in experienced hands. Patients should be counseled about this risk as part of the informed consent for the procedure.",
"     </li>",
"     <li>",
"      There is normally a significant amount of anatomic variability in the number and location of the bronchial arteries. Most individuals have one or two bronchial arteries on each side and a total of three or four arteries. Bronchial arteries usually arise from the aorta, but sometimes they originate from the intercostal arteries.",
"     </li>",
"     <li>",
"      It is rare for the bleeding rate to be sufficient (ie, &gt;1",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      for the extravasation of contrast to be visualized by arteriography. Arteriography may demonstrate a focal, tortuous, hypervascularized site, but such findings do not strictly prove that this is the bleeding site. Many chronic inflammatory lung lesions are jointly supplied by hypertrophied bronchial arteries and by collateral systemic arteries arising from the subclavian, axillary, intercostal, phrenic, or other arteries. Bleeding that arises from the systemic arteries will not be visualized by bronchial arteriography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pulmonary arteries are generally studied only if bronchial arteriography does not identify a bleeding source or if there is a high suspicion for arteriovenous malformation (AVMs) or pulmonary embolism. Overall, the pulmonary arteries are the bleeding source in fewer than 10 percent of patients with massive hemoptysis. The usual conditions that cause pulmonary arterial bleeding are pulmonary AVMs, Rasmussen's aneurysms, or iatrogenic pulmonary artery tears (eg, perforation from a Swan-Ganz catheter). The only indication for performing pulmonary arteriography prior to bronchial arteriography is the suspicion of one of these conditions.",
"   </p>",
"   <p>",
"    It is uncertain when potential systemic arterial supplies should be evaluated; examining each potential systemic arterial source can be a long and painstaking task that can increase the dye load substantially. Generally speaking, we believe that patients with massive hemoptysis who do not have a bleeding site identified by the combination of bronchoscopy, bronchial arteriography, and pulmonary arteriography should have their relevant systemic arteries examined. In addition, the systemic arteries should be evaluated when there is recurrence of massive hemoptysis, especially if it occurs early after therapeutic embolization. The systemic circulation is involved in as many as 5 to 10 percent of cases of ongoing hemoptysis.",
"   </p>",
"   <p>",
"    Arteriographic embolization successfully stops the pulmonary hemorrhage in more than 85 percent of attempted embolizations, especially if the bronchial, pulmonary,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic arterial circulations are well defined during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Early technical failures occur in 5 to 10 percent of attempted embolizations. Examples include the inability to cannulate the bronchial artery and failure to identify",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    embolize all of the collateral systemic feeder vessels (collateral systemic feeder vessels may arise from the gastric, intercostal, internal mammary, renal, or hepatic arteries) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/14,16-19\">",
"     14,16-19",
"    </a>",
"    ]. Rebleeding over the following 6 to 12 months occurs in a significant minority of patients who have undergone embolization (at least 10 to 20 percent); this may be due to incomplete embolization, revascularization, or recanalization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/15,20-23\">",
"     15,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of arteriographic embolization include bronchial wall necrosis and ischemic myelopathy (including paraplegia) due to inadvertent embolization of a spinal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/24\">",
"     24",
"    </a>",
"    ]. Such complications are uncommon when experienced operators perform the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unilateral, uncontrollable bleeding should be evaluated by a thoracic surgeon early. The purpose is to expedite surgical intervention later if the bleeding remains brisk despite measures to control it. Patients with massive hemoptysis are generally too ill for routine preoperative physiologic testing (eg, pulmonary function tests); thus, historical data (if available) must be used to estimate the patient's ability to undergo lung resection. Relative contraindications to surgery include severe underlying pulmonary disease, active tuberculosis, diffuse underlying lung disease (eg, cystic fibrosis, multiple AVMs, multifocal bronchiectasis), and diffuse alveolar hemorrhage.",
"   </p>",
"   <p>",
"    The morbidity and mortality of emergent surgery for persistent massive bleeding are greater than the morbidity and mortality of elective surgery in a nonbleeding patient. In most series of emergent therapy for massive hemoptysis, surgical mortality was approximately 20 percent and surgical morbidity was 25 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of these series were reported several decades ago and more recent data have not been reported.",
"   </p>",
"   <p>",
"    Common complications of surgery for massive hemoptysis include empyema, bronchopleural fistula, postoperative pulmonary hemorrhage, lung infarction, respiratory insufficiency, wound infection, and hemothorax. Empyema and bronchopleural fistula are especially frequent after emergent surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=see_link\">",
"     \"Sequelae and complications of pneumonectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Non-surgical versus surgical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective cohort studies have compared non-surgical interventions to surgery in patients with massive hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30454/abstract/5\">",
"     5",
"    </a>",
"    ]. Older studies suggest that surgery has lower mortality, but those studies may have been affected by bias because the highest risk patients were not surgical candidates and were managed with non-surgical interventions. Higher quality studies from the 1980s onward suggest that the mortality associated with non-surgical therapies and surgery are similar among patients who qualified as surgical candidates. However, patients managed non-surgically probably have a higher risk of rebleeding within the first six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step in managing massive hemoptysis is to determine which lung is likely bleeding. Patients should be immediately placed into a position in which the lung that is presumed to be bleeding is in the dependent position. (See",
"      <a class=\"local\" href=\"#H4655275\">",
"       'Identify which side is bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4655266\">",
"       'Position the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with massive hemoptysis who have severe shortness of breath, poor gas exchange, hemodynamic instability, or rapid ongoing hemoptysis, should be intubated. If the bleeding is bilateral, routine endotracheal intubation with a large bore endotracheal tube is appropriate. If bleeding is unilateral, it may be possible to protect the nonbleeding lung from spillage by using of one of the following techniques for intubation and mechanical ventilation: unilateral lung ventilation using a standard, single-lumen endotracheal tube advanced into the right or left mainstem bronchus or independent lung ventilation using a double-lumen endotracheal tube. (See",
"      <a class=\"local\" href=\"#H4655170\">",
"       'Establish a patent airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no ventilatory strategies or resuscitation strategies that are unique to patients with massive hemoptysis. (See",
"      <a class=\"local\" href=\"#H4655178\">",
"       'Insure adequate gas exchange'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4655222\">",
"       'Insure adequate cardiovascular function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with massive hemoptysis should have known or suspected coagulation abnormalities rapidly reversed. (See",
"      <a class=\"local\" href=\"#H7235375\">",
"       'Blood products'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with massive hemoptysis, we suggest flexible bronchoscopy at the bedside as the initial intervention to assess and attempt to control the bleeding, rather than arteriographic embolization or surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Bronchoscopic strategies to control pulmonary hemorrhage include balloon tamponade, iced saline lavage, administration of a topical vasoconstrictor or a topical coagulant, laser therapy, and electrocautery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with massive hemoptysis who continue to bleed despite a flexible bronchoscopic intervention and are stable enough to leave the intensive care unit for a procedure, we suggest arteriographic embolization rather than surgery during active bleeding episodes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Arteriography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who continue to bleed despite both a flexible bronchoscopic intervention and arteriographic embolization may benefit from another attempt at bronchoscopic bleeding control via rigid bronchoscopy. If the bleeding cannot be controlled via rigid bronchoscopy, surgery may be the best option. Similarly, patients who continue to bleed despite a flexible bronchoscopic intervention and are too unstable to go to the radiographic suite for a procedure may benefit from this approach. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/1\">",
"      Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/2\">",
"      Anantham D, Jagadesan R, Tiew PE. Clinical review: Independent lung ventilation in critical care. Crit Care 2005; 9:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/3\">",
"      Lordan JL, Gascoigne A, Corris PA. The pulmonary physician in critical care * Illustrative case 7: Assessment and management of massive haemoptysis. Thorax 2003; 58:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/4\">",
"      Conlan AA, Hurwitz SS, Krige L, et al. Massive hemoptysis. Review of 123 cases. J Thorac Cardiovasc Surg 1983; 85:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/5\">",
"      Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management. Clin Chest Med 1994; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/6\">",
"      de Gracia J, de la Rosa D, Catal&aacute;n E, et al. Use of endoscopic fibrinogen-thrombin in the treatment of severe hemoptysis. Respir Med 2003; 97:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/7\">",
"      Roberts AC. Bronchial artery embolization therapy. J Thorac Imaging 1990; 5:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/8\">",
"      Cremaschi P, Nascimbene C, Vitulo P, et al. Therapeutic embolization of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis. Angiology 1993; 44:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/9\">",
"      Keller FS, Rosch J, Loflin TG, et al. Nonbronchial systemic collateral arteries: significance in percutaneous embolotherapy for hemoptysis. Radiology 1987; 164:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/10\">",
"      Nath H. When does bronchial arterial embolization fail to control hemoptysis? Chest 1990; 97:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/11\">",
"      Yoon W, Kim JK, Kim YH, et al. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review. Radiographics 2002; 22:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/12\">",
"      Chun HJ, Byun JY, Yoo SS, Choi BG. Added benefit of thoracic aortography after transarterial embolization in patients with hemoptysis. AJR Am J Roentgenol 2003; 180:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/13\">",
"      Swanson KL, Johnson CM, Prakash UB, et al. Bronchial artery embolization : experience with 54 patients. Chest 2002; 121:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/14\">",
"      Remy-Jardin M, Bouaziz N, Dumont P, et al. Bronchial and nonbronchial systemic arteries at multi-detector row CT angiography: comparison with conventional angiography. Radiology 2004; 233:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/15\">",
"      Menchini L, Remy-Jardin M, Faivre JB, et al. Cryptogenic haemoptysis in smokers: angiography and results of embolisation in 35 patients. Eur Respir J 2009; 34:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/16\">",
"      Sellars N, Belli AM. Non-bronchial collateral supply from the left gastric artery in massive haemoptysis. Eur Radiol 2001; 11:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/17\">",
"      Vujic I, Pyle R, Parker E, Mithoefer J. Control of massive hemoptysis by embolization of intercostal arteries. Radiology 1980; 137:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/18\">",
"      Jardin M, Remy J. Control of hemoptysis: systemic angiography and anastomoses of the internal mammary artery. Radiology 1988; 168:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/19\">",
"      Chun HJ, Yoo SS, Kim HH, et al. Nonbronchial collateral supply from the hepatic arteries of a patient with hemoptysis. AJR Am J Roentgenol 2003; 180:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/20\">",
"      Mal H, Rullon I, Mellot F, et al. Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest 1999; 115:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/21\">",
"      White RI Jr. Bronchial artery embolotherapy for control of acute hemoptysis: analysis of outcome. Chest 1999; 115:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/22\">",
"      Osaki S, Nakanishi Y, Wataya H, et al. Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 2000; 67:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/23\">",
"      Barben J, Robertson D, Olinsky A, Ditchfield M. Bronchial artery embolization for hemoptysis in young patients with cystic fibrosis. Radiology 2002; 224:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/24\">",
"      Uflacker R, Kaemmerer A, Neves C, Picon PD. Management of massive hemoptysis by bronchial artery embolization. Radiology 1983; 146:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30454/abstract/25\">",
"      Wong ML, Szkup P, Hopley MJ. Percutaneous embolotherapy for life-threatening hemoptysis. Chest 2002; 121:95.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4393 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30454=[""].join("\n");
var outline_f29_47_30454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4655275\">",
"      IDENTIFY WHICH SIDE IS BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4655266\">",
"      POSITION THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4655170\">",
"      ESTABLISH A PATENT AIRWAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4655178\">",
"      INSURE ADEQUATE GAS EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4655222\">",
"      INSURE ADEQUATE CARDIOVASCULAR FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4655186\">",
"      CONTROL THE BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7235390\">",
"      Non-surgical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7235375\">",
"      - Blood products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Non-surgical versus surgical outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26838?source=related_link\">",
"      Massive hemoptysis: Causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29558?source=related_link\">",
"      Overview of massive hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=related_link\">",
"      Sequelae and complications of pneumonectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_47_30455="ECG Ventricular fibrillation tutorial";
var content_f29_47_30455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1050px;\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Single lead electrocardiogram (ECG) showing ventricular fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 121px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAB5AcwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0nwV4U0W48LeG5ZvDWhTSy6XFI7yW6FpCUjJZiUPzc+/U8+ura+D9BP2P/ilvD7boCfmto/m+5yf3fXn36mk8CW27wh4X/wBCs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNZQiuVaf19x7lWpLml73fr/i/vf1+XJjwpov8AwlOhxDw1oRik0u6kZDbptch7UBmGz7w3HHX7x59dW18H6Cfsf/FLeH23QE/NbR/N9zk/u+vPv1NJ9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzQoq70/q3oE6krfF36/4v739flkWvg/QT9j/AOKW8PtugJ+a2j+b7nJ/d9effqayvBXhTRbjwt4blm8NaFNLLpcUjvJboWkJSMlmJQ/Nz79Tz69Za2277J/oVm26At8zfe+7yfl68+/U81j+BLbd4Q8L/wChWbbtKhb5m+9+7j5Py9effqeaHFc23f8ArYHUlyv3vx/xf3v6/JbXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U1lDwpov/AAlOhxDw1oRik0u6kZDbptch7UBmGz7w3HHX7x59estbbd9k/wBCs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqeaJxVtv6v6Aqkrv3u/X/F/e/r8ltfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TRa+D9BP2P/ilvD7boCfmto/m+5yf3fXn36mte1tt32T/AEKzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmrcV2/r7iZVZa+936/4v739flyfgrwpotx4W8NyzeGtCmll0uKR3kt0LSEpGSzEofm59+p59dW18H6Cfsf/ABS3h9t0BPzW0fzfc5P7vrz79TSeBLbd4Q8L/wChWbbtKhb5m+9+7j5Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmohFcq0/r7iqtSXNL3u/X/ABf3v6/Lkx4U0X/hKdDiHhrQjFJpd1IyG3Ta5D2oDMNn3huOOv3jz66tr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqaT7Nu8X6D/oVm27Srtvmb737y05Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmhRV3p/VvQJ1JW+Lv1/xf3v6/LItfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TWV4K8KaLceFvDcs3hrQppZdLikd5LdC0hKRksxKH5uffqefXrLW23fZP9Cs23QFvmb733eT8vXn36nmsfwJbbvCHhf8A0KzbdpULfM33v3cfJ+Xrz79TzQ4rm27/ANbA6kuV+9+P+L+9/X5La+D9BP2P/ilvD7boCfmto/m+5yf3fXn36msoeFNF/wCEp0OIeGtCMUml3UjIbdNrkPagMw2feG446/ePPr1lrbbvsn+hWbboC3zN977vJ+Xrz79TzWP9m3eL9B/0KzbdpV23zN9795acn5evPv1PNE4q239X9AVSV373fr/i/vf1+S2vg/QT9j/4pbw+26An5raP5vucn93159+potfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TWva2277J/oVm26At8zfe+7yfl68+/U80Wttu+yf6FZtugLfM33vu8n5evPv1PNW4rt/X3Eyqy197v1/xf3v6/Lk/BXhTRbjwt4blm8NaFNLLpcUjvJboWkJSMlmJQ/Nz79Tz66tr4P0E/Y/8AilvD7boCfmto/m+5yf3fXn36mk8CW27wh4X/ANCs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNRCK5Vp/X3FVakuaXvd+v8Ai/vf1+XJjwpov/CU6HEPDWhGKTS7qRkNum1yHtQGYbPvDccdfvHn11bXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U0n2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNCirvT+regTqSt8Xfr/i/vf1+WRa+D9BP2P/ilvD7boCfmto/m+5yf3fXn36msrwV4U0W48LeG5ZvDWhTSy6XFI7yW6FpCUjJZiUPzc+/U8+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmhxXNt3/rYHUlyv3vx/xf3v6/JbXwfoJ+x/8AFLeH23QE/NbR/N9zk/u+vPv1Nc3rml+GdC1HTb7UvDujJpkOkXVxcbLHzchZLUeYyJExJUM3ODgFiSBk13drbbvsn+hWbboC3zN977vJ+Xrz79TzWP8AZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzROKtt/V/QFUld+936/4v739flyPgvV/hz4t1CCy8O6Lo+oTxxESldIkVEOMgyOYNqk7Wxk8nIBzjN7TD4Iu/E9t4ei8NaYdXFs8hhl0aSMMgIHml2g27cqQHyVJOASSM+T+Bov+FU/HaXw9dwQvoniKOM2YkOVXzGPkHo7ZD74ecZzuPGK9o+HsY1kSeJDZQsuqIVtVnVoz9khbbExBTneWkmDEZxPtyQq1biuxgsROV05a69X5/wB4j8FeFNFuPC3huWbw1oU0sulxSO8luhaQlIyWYlD83Pv1PPrq2vg/QT9j/wCKW8PtugJ+a2j+b7nJ/d9effqaTwJbbvCHhf8A0KzbdpULfM33v3cfJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U81EIrlWn9fcb1akuaXvd+v+L+9/X5cmPCmi/8JTocQ8NaEYpNLupGQ26bXIe1AZhs+8Nxx1+8efXVtfB+gn7H/wAUt4fbdAT81tH833OT+768+/U0n2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNCirvT+regTqSt8Xfr/AIv739flkWvg/QT9j/4pbw+26An5raP5vucn93159+prK8FeFNFuPC3huWbw1oU0sulxSO8luhaQlIyWYlD83Pv1PPr1lrbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmhxXNt3/rYHUlyv3vx/wAX97+vyW18H6Cfsf8AxS3h9t0BPzW0fzfc5P7vrz79TWUPCmi/8JTocQ8NaEYpNLupGQ26bXIe1AZhs+8Nxx1+8efXrLW23fZP9Cs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqeaJxVtv6v6Aqkrv3u/X/F/e/r8ltfB+gn7H/wAUt4fbdAT81tH833OT+768+/U0Wvg/QT9j/wCKW8PtugJ+a2j+b7nJ/d9effqa17W23fZP9Cs23QFvmb733eT8vXn36nmi1tt32T/QrNt0Bb5m+993k/L159+p5q3Fdv6+4mVWWvvd+v8Ai/vf1+XJ+CvCmi3Hhbw3LN4a0KaWXS4pHeS3QtISkZLMSh+bn36nn11bXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U0ngS23eEPC/+hWbbtKhb5m+9+7j5Py9effqea2LW23fZP8AQrNt0Bb5m+993k/L159+p5qIRXKtP6+4qrUlzS97v1/xf3v6/Lkx4U0X/hKdDiHhrQjFJpd1IyG3Ta5D2oDMNn3huOOv3jz66tr4P0E/Y/8AilvD7boCfmto/m+5yf3fXn36mk+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5oUVd6f1b0CdSVvi79f8X97+vyyLXwfoJ+x/8AFLeH23QE/NbR/N9zk/u+vPv1NZXgrwpotx4W8NyzeGtCmll0uKR3kt0LSEpGSzEofm59+p59estbbd9k/wBCs23QFvmb733eT8vXn36nmsfwJbbvCHhf/QrNt2lQt8zfe/dx8n5evPv1PNDiubbv/WwOpLlfvfj/AIv739fktr4P0E/Y/wDilvD7boCfmto/m+5yf3fXn36msoeFNF/4SnQ4h4a0IxSaXdSMht02uQ9qAzDZ94bjjr948+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/2bd4v0H/AEKzbdpV23zN9795acn5evPv1PNE4q239X9AVSV373fr/i/vf1+S2vg/QT9j/wCKW8PtugJ+a2j+b7nJ/d9effqaLXwfoJ+x/wDFLeH23QE/NbR/N9zk/u+vPv1Na9rbbvsn+hWbboC3zN977vJ+Xrz79TzRa2277J/oVm26At8zfe+7yfl68+/U81biu39fcTKrLX3u/X/F/e/r8uT8FeFNFuPC3huWbw1oU0sulxSO8luhaQlIyWYlD83Pv1PPrq2vg/QT9j/4pbw+26An5raP5vucn93159+ppPAltu8IeF/9Cs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNRCK5Vp/X3FVakuaXvd+v+L+9/X5cmPCmi/8ACU6HEPDWhGKTS7qRkNum1yHtQGYbPvDccdfvHn11bXwfoJ+x/wDFLeH23QE/NbR/N9zk/u+vPv1NJ9m3eL9B/wBCs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U80KKu9P6t6BOpK3xd+v+L+9/X5ZFr4P0E/Y/8AilvD7boCfmto/m+5yf3fXn36msrwV4U0W48LeG5ZvDWhTSy6XFI7yW6FpCUjJZiUPzc+/U8+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/+hWbbtKhb5m+9+7j5Py9effqeaHFc23f+tgdSXK/e/H/F/e/r8ltfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TU1l4O0FrOA/8Ip4efManc1tHk8dT+7rRtbbd9k/0KzbdAW+Zvvfd5Py9effqeams7TdZwN/Z9i+UU7mbk8dT8nWqlFdv6+4zq1ZW+L8fN/3jjfBSa1/wi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+urajXm+x/8AFP8Ah9t0Bb5tSk+b7vJ/0brz79TSeBLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqeamC91f1+hpVmuaXz6/4v739flyYTWm8U6GW0LQmlOl3RVTqD7XG+1yzH7Pww4wMHO48jHOrajXm+x/8U/4fbdAW+bUpPm+7yf9G68+/U0n2bd4v0H/AEKzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzQlq/66egTmrff1/wAX97+vyyLUa832P/in/D7boC3zalJ833eT/o3Xn36msrwUmtf8It4bEOhaFLEdLiKNJqDqzjZHhmAtzhuemT1PPr1lrbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmhr3vv/AK2BzXK/8/8AF/e/r8ltRrzfY/8Ain/D7boC3zalJ833eT/o3Xn36msoJrTeKdDLaFoTSnS7oqp1B9rjfa5Zj9n4YcYGDnceRjnrLW23fZP9Cs23QFvmb733eT8vXn36nmsf7Nu8X6D/AKFZtu0q7b5m+9+8tOT8vXn36nmia0/rv6Apq7+fX/F/e/r8ltRrzfY/+Kf8PtugLfNqUnzfd5P+jdeffqaLUa832P8A4p/w+26At82pSfN93k/6N159+prXtbbd9k/0KzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmra/r+kTKa1+fX/F/e/r8uT8FJrX/AAi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+urajXm+x/8U/4fbdAW+bUpPm+7yf9G68+/U0ngS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5qIL3V/X6FVZrml8+v+L+9/X5cmE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxzq2o15vsf/FP+H23QFvm1KT5vu8n/AEbrz79TSfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U80Jav8Arp6BOat9/X/F/e/r8si1GvN9j/4p/wAPtugLfNqUnzfd5P8Ao3Xn36msrwUmtf8ACLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz69Za2277J/oVm26At8zfe+7yfl68+/U81j+BLbd4Q8L/wChWbbtKhb5m+9+7j5Py9effqeaGve+/wDrYHNcr/z/AMX97+vyW1GvN9j/AOKf8PtugLfNqUnzfd5P+jdeffqaygmtN4p0MtoWhNKdLuiqnUH2uN9rlmP2fhhxgYOdx5GOestbbd9k/wBCs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqeaJrT+u/oCmrv59f8X97+vyW1GvN9j/4p/wAPtugLfNqUnzfd5P8Ao3Xn36mi1GvN9j/4p/w+26At82pSfN93k/6N159+prXtbbd9k/0KzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmra/r+kTKa1+fX/F/e/r8uT8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz66tqNeb7H/xT/h9t0Bb5tSk+b7vJ/wBG68+/U0ngS23eEPC/+hWbbtKhb5m+9+7j5Py9effqea2LW23fZP8AQrNt0Bb5m+993k/L159+p5qIL3V/X6FVZrml8+v+L+9/X5cmE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxzq2o15vsf/ABT/AIfbdAW+bUpPm+7yf9G68+/U0n2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNCWr/rp6BOat9/X/F/e/r8si1GvN9j/wCKf8PtugLfNqUnzfd5P+jdeffqayvBSa1/wi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmhr3vv/rYHNcr/wA/8X97+vyW1GvN9j/4p/w+26At82pSfN93k/6N159+prKCa03inQy2haE0p0u6KqdQfa432uWY/Z+GHGBg53HkY56y1tt32T/QrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmia0/rv6Apq7+fX/ABf3v6/LzX4yfDjxH8QtO8PLaWGkWd1aEnfHfs++OQxq7MDCvK4VvvdAwAYkCtPxV411XwNpUVy/w/sp9E0+3jSae2vljij3eUqhVeFS+N6DKAqN2N2VYD0+1tt32T/QrNt0Bb5m+993k/L159+p5rg/Fmi+ONS1vSpPD9p4Q/su3hEyQ6m87GeYbSJZFjUDKk/KpLAHLn5gmzS39f0jCrJR5pLd9vn/AHjQ8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz66tqNeb7H/wAU/wCH23QFvm1KT5vu8n/RuvPv1NN8A2v/ABR3hYGztJCdJhOXP3/3cfzN8nXn9TWza2277J/oVm26At8zfe+7yfl68+/U81EV7q/r9DepUXM/n1/xf3v6/LkwmtN4p0MtoWhNKdLuiqnUH2uN9rlmP2fhhxgYOdx5GOdW1GvN9j/4p/w+26At82pSfN93k/6N159+ppPs27xfoP8AoVm27Srtvmb737y05Py9effqea2LW23fZP8AQrNt0Bb5m+993k/L159+p5pJav8Arp6BOat9/X/F/e/r8si1GvN9j/4p/wAPtugLfNqUnzfd5P8Ao3Xn36msrwUmtf8ACLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz69Za2277J/oVm26At8zfe+7yfl68+/U81j+BLbd4Q8L/wChWbbtKhb5m+9+7j5Py9effqeaGve+/wDrYHNcr/z/AMX97+vyW1GvN9j/AOKf8PtugLfNqUnzfd5P+jdeffqaygmtN4p0MtoWhNKdLuiqnUH2uN9rlmP2fhhxgYOdx5GOestbbd9k/wBCs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqeaJrT+u/oCmrv59f8X97+vyW1GvN9j/4p/wAPtugLfNqUnzfd5P8Ao3Xn36mi1GvN9j/4p/w+26At82pSfN93k/6N159+prXtbbd9k/0KzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmra/r+kTKa1+fX/F/e/r8uT8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz66tqNeb7H/xT/h9t0Bb5tSk+b7vJ/wBG68+/U0ngS23eEPC/+hWbbtKhb5m+9+7j5Py9effqea2LW23fZP8AQrNt0Bb5m+993k/L159+p5qIL3V/X6FVZrml8+v+L+9/X5cmE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxzq2o15vsf/ABT/AIfbdAW+bUpPm+7yf9G68+/U0n2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNCWr/rp6BOat9/X/F/e/r8si1GvN9j/wCKf8PtugLfNqUnzfd5P+jdeffqayvBSa1/wi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmhr3vv/rYHNcr/wA/8X97+vyW1GvN9j/4p/w+26At82pSfN93k/6N159+prKCa03inQy2haE0p0u6KqdQfa432uWY/Z+GHGBg53HkY56y1tt32T/QrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmia0/rv6Apq7+fX/ABf3v6/JbUa832P/AIp/w+26At82pSfN93k/6N159+potRrzfY/+Kf8AD7boC3zalJ833eT/AKN159+prXtbbd9k/wBCs23QFvmb733eT8vXn36nmi1tt32T/QrNt0Bb5m+993k/L159+p5q2v6/pEymtfn1/wAX97+vy5PwUmtf8It4bEOhaFLEdLiKNJqDqzjZHhmAtzhuemT1PPrq2o15vsf/ABT/AIfbdAW+bUpPm+7yf9G68+/U0ngS23eEPC/+hWbbtKhb5m+9+7j5Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmogvdX9foVVmuaXz6/wCL+9/X5cmE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxzq2o15vsf8AxT/h9t0Bb5tSk+b7vJ/0brz79TSfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U80Jav+unoE5q339f8X97+vyyLUa832P8A4p/w+26At82pSfN93k/6N159+prK8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz69Za2277J/oVm26At8zfe+7yfl68+/U81j+BLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5oa977/62BzXK/wDP/F/e/r8ltRrzfY/+Kf8AD7boC3zalJ833eT/AKN159+pqazTXms4G/4R3w82Y1O5tSkyeOp/0atG1tt32T/QrNt0Bb5m+993k/L159+p5qaztN1nA39n2L5RTuZuTx1PydaqS/r+kZ1ait/wfN/3jB8CW27wh4X/ANCs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNcn4K8KaLceFvDcs3hrQppZdLikd5LdC0hKRksxKH5uffqefXVtfB+gn7H/AMUt4fbdAT81tH833OT+768+/U1ML8q0/r7jSrKPNLXv/wC3f3v6/JPs27xfoP8AoVm27Srtvmb737y05Py9effqea2LW23fZP8AQrNt0Bb5m+993k/L159+p5rkx4U0X/hKdDiHhrQjFJpd1IyG3Ta5D2oDMNn3huOOv3jz66tr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqaFe7/rp6BOUbb9//AG7+9/X5a9rbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv8A6FZtu0qFvmb737uPk/L159+p5pbXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U1leCvCmi3Hhbw3LN4a0KaWXS4pHeS3QtISkZLMSh+bn36nn1Hfm27/1sDlHlev8AXvf3v6/LrLW23fZP9Cs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqeaW18H6Cfsf/FLeH23QE/NbR/N9zk/u+vPv1NZQ8KaL/wAJTocQ8NaEYpNLupGQ26bXIe1AZhs+8Nxx1+8efUne39d/QFKN3r3/APbv739fl1lrbbvsn+hWbboC3zN977vJ+Xrz79TzRa2277J/oVm26At8zfe+7yfl68+/U81kWvg/QT9j/wCKW8PtugJ+a2j+b7nJ/d9effqaLXwfoJ+x/wDFLeH23QE/NbR/N9zk/u+vPv1NW79v6+4mTjrr3/8Abv7wngS23eEPC/8AoVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5rk/BXhTRbjwt4blm8NaFNLLpcUjvJboWkJSMlmJQ/Nz79Tz66tr4P0E/Y/8AilvD7boCfmto/m+5yf3fXn36mohflWn9fcVVlHmlr3/9u/vf1+SfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U81yY8KaL/AMJTocQ8NaEYpNLupGQ26bXIe1AZhs+8Nxx1+8efXVtfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TQr3f9dPQJyjbfv8A+3f3v6/LXtbbd9k/0KzbdAW+Zvvfd5Py9effqeax/Altu8IeF/8AQrNt2lQt8zfe/dx8n5evPv1PNLa+D9BP2P8A4pbw+26An5raP5vucn93159+prK8FeFNFuPC3huWbw1oU0sulxSO8luhaQlIyWYlD83Pv1PPqO/Nt3/rYHKPK9f697+9/X5dZa2277J/oVm26At8zfe+7yfl68+/U81j/Zt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzS2vg/QT9j/AOKW8PtugJ+a2j+b7nJ/d9effqayh4U0X/hKdDiHhrQjFJpd1IyG3Ta5D2oDMNn3huOOv3jz6k72/rv6ApRu9e//ALd/e/r8ustbbd9k/wBCs23QFvmb733eT8vXn36nmi1tt32T/QrNt0Bb5m+993k/L159+p5rItfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TRa+D9BP2P/ilvD7boCfmto/m+5yf3fXn36mrd+39fcTJx117/APt394TwJbbvCHhf/QrNt2lQt8zfe/dx8n5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXJ+CvCmi3Hhbw3LN4a0KaWXS4pHeS3QtISkZLMSh+bn36nn11bXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U1EL8q0/r7iqso80te/8A7d/e/r8k+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5rkx4U0X/hKdDiHhrQjFJpd1IyG3Ta5D2oDMNn3huOOv3jz66tr4P0E/Y/8AilvD7boCfmto/m+5yf3fXn36mhXu/wCunoE5Rtv3/wDbv739flr2ttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/+hWbbtKhb5m+9+7j5Py9effqeaW18H6Cfsf/ABS3h9t0BPzW0fzfc5P7vrz79TWV4K8KaLceFvDcs3hrQppZdLikd5LdC0hKRksxKH5uffqefUd+bbv/AFsDlHlev9e9/e/r8ustbbd9k/0KzbdAW+Zvvfd5Py9effqeax/s27xfoP8AoVm27Srtvmb737y05Py9effqeaW18H6Cfsf/ABS3h9t0BPzW0fzfc5P7vrz79TWUPCmi/wDCU6HEPDWhGKTS7qRkNum1yHtQGYbPvDccdfvHn1J3t/Xf0BSjd69//bv739fl1lrbbvsn+hWbboC3zN977vJ+Xrz79TzRa2277J/oVm26At8zfe+7yfl68+/U81kWvg/QT9j/AOKW8PtugJ+a2j+b7nJ/d9effqaLXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U1bv2/r7iZOOuvf/ANu/vCeBLbd4Q8L/AOhWbbtKhb5m+9+7j5Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmuT8FeFNFuPC3huWbw1oU0sulxSO8luhaQlIyWYlD83Pv1PPrq2vg/QT9j/AOKW8PtugJ+a2j+b7nJ/d9effqaiF+Vaf19xVWUeaWvf/wBu/vf1+SfZt3i/Qf8AQrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNcmPCmi/8JTocQ8NaEYpNLupGQ26bXIe1AZhs+8Nxx1+8efXVtfB+gn7H/xS3h9t0BPzW0fzfc5P7vrz79TQr3f9dPQJyjbfv/7d/e/r8te1tt32T/QrNt0Bb5m+993k/L159+p5rH8CW27wh4X/ANCs23aVC3zN9793Hyfl68+/U80tr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqayvBXhTRbjwt4blm8NaFNLLpcUjvJboWkJSMlmJQ/Nz79Tz6jvzbd/62ByjyvX+ve/vf1+XWWttu+yf6FZtugLfM33vu8n5evPv1PNY/wBm3eL9B/0KzbdpV23zN9795acn5evPv1PNLa+D9BP2P/ilvD7boCfmto/m+5yf3fXn36msoeFNF/4SnQ4h4a0IxSaXdSMht02uQ9qAzDZ94bjjr948+pO9v67+gKUbvXv/AO3f3v6/LrLW23fZP9Cs23QFvmb733eT8vXn36nmi1tt32T/AEKzbdAW+Zvvfd5Py9effqeayLXwfoJ+x/8AFLeH23QE/NbR/N9zk/u+vPv1NFr4P0E/Y/8AilvD7boCfmto/m+5yf3fXn36mrd+39fcTJx117/+3f3hPAltu8IeF/8AQrNt2lQt8zfe/dx8n5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXJ+CvCmi3Hhbw3LN4a0KaWXS4pHeS3QtISkZLMSh+bn36nn11bXwfoJ+x/8AFLeH23QE/NbR/N9zk/u+vPv1NRC/KtP6+4qrKPNLXv8A+3f3v6/JPs27xfoP+hWbbtKu2+ZvvfvLTk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqea5MeFNF/wCEp0OIeGtCMUml3UjIbdNrkPagMw2feG446/ePPrq2vg/QT9j/AOKW8PtugJ+a2j+b7nJ/d9effqaFe7/rp6BOUbb9/wD27+9/X5a9rbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmltfB+gn7H/AMUt4fbdAT81tH833OT+768+/U1leCvCmi3Hhbw3LN4a0KaWXS4pHeS3QtISkZLMSh+bn36nn1Hfm27/ANbA5R5Xr/Xvf3v6/LrLW23fZP8AQrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmltfB+gn7H/AMUt4fbdAT81tH833OT+768+/U1lDwpov/CU6HEPDWhGKTS7qRkNum1yHtQGYbPvDccdfvHn1J3t/Xf0BSjd69//AG7+9/X5dZa2277J/oVm26At8zfe+7yfl68+/U80Wttu+yf6FZtugLfM33vu8n5evPv1PNZFr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqaLXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U1bv2/r7iZOOuvf8A9u/vCeBLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5rYtbbd9k/wBCs23QFvmb733eT8vXn36nmuT8FeFNFuPC3huWbw1oU0sulxSO8luhaQlIyWYlD83Pv1PPrq2vg/QT9j/4pbw+26An5raP5vucn93159+pqIX5Vp/X3FVZR5pa9/8A27+9/X5J9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXJjwpov/CU6HEPDWhGKTS7qRkNum1yHtQGYbPvDccdfvHn11bXwfoJ+x/8AFLeH23QE/NbR/N9zk/u+vPv1NCvd/wBdPQJyjbfv/wC3f3v6/LXtbbd9k/0KzbdAW+Zvvfd5Py9effqeax/Altu8IeF/9Cs23aVC3zN9793Hyfl68+/U80tr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqayvBXhTRbjwt4blm8NaFNLLpcUjvJboWkJSMlmJQ/Nz79Tz6jvzbd/62ByjyvX+ve/vf1+XWWttu+yf6FZtugLfM33vu8n5evPv1PNTWdpus4G/s+xfKKdzNyeOp+TrWFa+D9BP2P/ilvD7boCfmto/m+5yf3fXn36mprLwdoLWcB/4RTw8+Y1O5raPJ46n93VSv2/r7jOrKNt/6u/7xB4Ett3hDwv8A6FZtu0qFvmb737uPk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqea5PwUmtf8It4bEOhaFLEdLiKNJqDqzjZHhmAtzhuemT1PPrq2o15vsf/ABT/AIfbdAW+bUpPm+7yf9G68+/U1MPhX9foaVb80te/X/F/e/r8k+zbvF+g/wChWbbtKu2+ZvvfvLTk/L159+p5rYtbbd9k/wBCs23QFvmb733eT8vXn36nmuB8OazdeJdR8OarpGlaFdW1xpl75Tm9lRZAs1ujs262DBgy4Awc5JyMDdP4z8T6p4N8Jtr+oeGdGubW2gRnji1Ft775I0B5twM5cd/X8XHd/wBdPQVR+7e/R9f8X97+vy7e1tt32T/QrNt0Bb5m+993k/L159+p5rH8CW27wh4X/wBCs23aVC3zN9793Hyfl68+/U80tqNeb7H/AMU/4fbdAW+bUpPm+7yf9G68+/U1leCk1r/hFvDYh0LQpYjpcRRpNQdWcbI8MwFucNz0yep59U/i+/8ArYbvyvX8f8X97+vy6y1tt32T/QrNt0Bb5m+993k/L159+p5rH+zbvF+g/wChWbbtKu2+ZvvfvLTk/L159+p5pbUa832P/in/AA+26At82pSfN93k/wCjdeffqaygmtN4p0MtoWhNKdLuiqnUH2uN9rlmP2fhhxgYOdx5GOSe39d/QFe7179f8X97+vy6y1tt32T/AEKzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmsi1GvN9j/4p/w+26At82pSfN93k/6N159+potRrzfY/wDin/D7boC3zalJ833eT/o3Xn36mrb/AK/pEyvrr36/4v739fkngS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5rk/BSa1/wi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+urajXm+x/8AFP8Ah9t0Bb5tSk+b7vJ/0brz79TUQ+Ff1+hVW/NLXv1/xf3v6/JPs27xfoP+hWbbtKu2+ZvvfvLTk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqea5MJrTeKdDLaFoTSnS7oqp1B9rjfa5Zj9n4YcYGDnceRjnVtRrzfY/8Ain/D7boC3zalJ833eT/o3Xn36mhbv+unoE72379f8X97+vy17W23fZP9Cs23QFvmb733eT8vXn36nmsfwJbbvCHhf/QrNt2lQt8zfe/dx8n5evPv1PNLajXm+x/8U/4fbdAW+bUpPm+7yf8ARuvPv1NeLfEfxXf+E/BHwznktba3j32t1ss7yTzL6CKJC6SjylUBt6ZBZuW6Ngmm/i+/+thTfLFtv8f8X97+vy+gLW23fZP9Cs23QFvmb733eT8vXn36nmsf7Nu8X6D/AKFZtu0q7b5m+9+8tOT8vXn36nmltRrzfY/+Kf8AD7boC3zalJ833eT/AKN159+prye08Xag/wC0VbaK2j2b3I0cWC2z3zfZvMKi6M27ys7igCn5M5A5wKJK6/r/ACJlPku7+W/fm/vHt9rbbvsn+hWbboC3zN977vJ+Xrz79TzRa2277J/oVm26At8zfe+7yfl68+/U81kWo15vsf8AxT/h9t0Bb5tSk+b7vJ/0brz79TRajXm+x/8AFP8Ah9t0Bb5tSk+b7vJ/0brz79TVN/1/SHK+uvfr/i/vf1+SeBLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqea8n+DfjseKrGDRtI0bRzfaParbzQ3l80ckyoETzgBAwIJyOpIJ5xkbu3u77VdM0z+0b/RPD6WdtZSXM8jahK2ERVZnIFqSSBngAnk/jEPhX9foVUvzS179f8X94s/Zt3i/Qf8AQrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNcNompXuu6r4b1LS9L8PXlvc6VdPC6ai5SRfMtgxY/Z8q4OBtIJyWBIIwc34keM9Y8D6Z4c1G90Xw9FZ3V5FbXEj3Ms/7tl3MxAhUqQFPzAPjn5Wpx3f9dPQVR+7e/fr/i/vf1+Xpdrbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv8A6FZtu0qFvmb737uPk/L159+p5pbUa832P/in/D7boC3zalJ833eT/o3Xn36muP8ABHiG/N34d8LweHtKluh4bg1NZpb5lSSElIwWxASJMjOORyfmNJv3vv8A62CTtF3f4/4v739fl6Pa2277J/oVm26At8zfe+7yfl68+/U81j/Zt3i/Qf8AQrNt2lXbfM33v3lpyfl68+/U80tqNeb7H/xT/h9t0Bb5tSk+b7vJ/wBG68+/U1lBNabxToZbQtCaU6XdFVOoPtcb7XLMfs/DDjAwc7jyMck9v67+g1e7179f8X97+vy0b3W7PTfEfhbRbjTY5LrW4rgW7LjZmKNZGaQkZBx0wG5J6Vt2ttu+yf6FZtugLfM33vu8n5evPv1PNfNfxUvNZi+O/wAPY5ILa3m8uzMVvBeu0UnmXDKxZvLXbvA2thW+UD73SvfbUa832P8A4p/w+26At82pSfN93k/6N159+pq3/X9WMVJyclfZ9/J/3v6/JPAltu8IeF/9Cs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNcn4KTWv+EW8NiHQtCliOlxFGk1B1ZxsjwzAW5w3PTJ6nn11bUa832P8A4p/w+26At82pSfN93k/6N159+pqIfCv6/Q2q35pa9+v+L+9/X5J9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXJhNabxToZbQtCaU6XdFVOoPtcb7XLMfs/DDjAwc7jyMc6tqNeb7H/xT/h9t0Bb5tSk+b7vJ/wBG68+/U0Ld/wBdPQJ3tv36/wCL+9/X5a9rbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv/AKFZtu0qFvmb737uPk/L159+p5pbUa832P8A4p/w+26At82pSfN93k/6N159+prK8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz6j+L7/wCtgd+V6/j/AIv739fl1lrbbvsn+hWbboC3zN977vJ+Xrz79TzWP9m3eL9B/wBCs23aVdt8zfe/eWnJ+Xrz79TzS2o15vsf/FP+H23QFvm1KT5vu8n/AEbrz79TWUE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxyT2/rv6Ar3evfr/i/vf1+XWWttu+yf6FZtugLfM33vu8n5evPv1PNFrbbvsn+hWbboC3zN977vJ+Xrz79TzWRajXm+x/8U/4fbdAW+bUpPm+7yf9G68+/U0Wo15vsf8AxT/h9t0Bb5tSk+b7vJ/0brz79TVt/wBf0iZX1179f8X97+vyTwJbbvCHhf8A0KzbdpULfM33v3cfJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U81yfgpNa/4Rbw2IdC0KWI6XEUaTUHVnGyPDMBbnDc9MnqefXVtRrzfY/+Kf8AD7boC3zalJ833eT/AKN159+pqIfCv6/Qqrfmlr36/wCL+9/X5J9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXJhNabxToZbQtCaU6XdFVOoPtcb7XLMfs/DDjAwc7jyMc6tqNeb7H/wAU/wCH23QFvm1KT5vu8n/RuvPv1NC3f9dPQJ3tv36/4v739flr2ttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmqOp6tf6FpA1TWNK8N21hb2plmml1KTGPkGSPsxJYkgADJJbA5PNfwMdZk8JeGWttD0KaB9KhaN5L90aRfLjwzD7OcNg9MnqefVv4vv8A62E3o1f8f8X94661tt32T/QrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmvCPiP4i1iL46+AbOKPSUuLUW6C1gnWZN9w+yQSuYgys8ezgq20EMvJr2MJrTeKdDLaFoTSnS7oqp1B9rjfa5Zj9n4YcYGDnceRjknt/X+RMJ80pK+1+vk/739fl1lrbbvsn+hWbboC3zN977vJ+Xrz79TzRa2277J/oVm26At8zfe+7yfl68+/U81538NPHc3j2G5k0XQ9CYWMj2zrNqTq8gGzbNt+zkhWycbgDw3oay/GnxD1Tw54s8H+HY9D0BtR1aSASK1zLKvkySCMEnyUCsSGww342tlTkZr+v60JlNKPNfT19f739fl6B4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5rk/BSa1/wAIt4bEOhaFLEdLiKNJqDqzjZHhmAtzhuemT1PPrynwb+IepfECPUTb6JoLS2UrDyZLiWBhC23y2c+VIGb5XGQR0PyrxuiHwr+v0NKsvfav36+v97+vy7/7Nu8X6D/oVm27Srtvmb737y05Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmvMPGvi6fwfr/AIQutc0PRgmoRS2CONQIjUyPbkyzO0I2qu3k4bgk9ue4tRrzfY/+Kf8AD7boC3zalJ833eT/AKN159+poW7/AK6eg53tv36/4v739flr2ttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmltRrzfY/+Kf8PtugLfNqUnzfd5P+jdeffqa81t/iK3hiT4feHJvD2mXd3q9hapCVvXXasmyOOSXMGBkhuFLEYPtlv4vv/rYU5csXd9e/+L+9/X5ew2ttu+yf6FZtugLfM33vu8n5evPv1PNTWdpus4G/s+xfKKdzNyeOp+TrWFajXm+x/wDFP+H23QFvm1KT5vu8n/RuvPv1NTWaa81nA3/CO+HmzGp3NqUmTx1P+jU5f1/ViKt7b/j5v+8QeBLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5qLxlNcaZ4H1bULK3tI7q20e5uYpSAxDpFuVypQgkHBwcg5P4y+BLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5rmvjbeS6R8I9auoLKyLyWHkEvlsrM8UTNgAfMBISOeCe+MEgvdX9foOtKzlr36/4v7xxH7MF5Lqei6Pby2Vk6WEep20ZOQXUyWcuX4OSDMwBGOPpk6X7UN7LpvwrtIYrW0VNSnit5HwS+0Dzdw4GGzGo5zwzfWsv4B6TL4a+IGseDLmC0vZdMhmvPtRYhZUuBZlBtKnaVVBnk8uQDxk7fx00geJZPh/4TSzIl1bUPOd7eRUPkRR/vmLMOGCSbhw3Q9TgEirSf9dDFyaopN9LfjLz/AEO/+HiS3fgnwnPc21vcTz6PBLJJK5ZpWMcZLsSpJbJ9+p59ZPAltu8IeF/9Cs23aVC3zN9793Hyfl68+/U81zfwCmuNT+FXhae7t7S4kFtNCGcBcpFMY0yAnUKqjPJPJJznPSeBLbd4Q8L/AOhWbbtKhb5m+9+7j5Py9effqeaTXvL0f9bGlOd6V7/j5S/vf1+VXw/4l03VfGOpeGYLKAanpNtDLMJioWdZERg6YBJ27lDZHBcc888h8Z/Fp8B2mkavBZ6a19JYTw2qXEbSJM7S2hO4KBghBIeWA469AfMvhTcxad8am1eO4024sPEOrarpY88jZhPKmRkfOCXaSNRwc8gcsMdJ+07pL6ovhCzRbe1BstTvTIo3F/ItklweBgkKR3xn86lG5Ht9JO/db97+fn2PerW23fZP9Cs23QFvmb733eT8vXn36nmi1tt32T/QrNt0Bb5m+993k/L159+p5rn/AIaW27wD4O/0Kzbdotufmb737qLk/L159+p5rXtZrNtRtNP2aY1+bP7SbYzDzWjyq+YU25xnIzgjORmj+vz8ivaXjzX/AB9f739flQ8CW27wh4X/ANCs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNeeXHi7T/BPw58J3N3psN9f3mnQQ2GnwfNNezGOIAAbD6jJ5xnHJKhrHwb8V3PjHTruHWNL0m31zSriayvLeKUclSuJCuGI/iUHJBKOQewmC91f1+hdWp77V+/6/wB7+vy2beeyuvHumWVuulz3ltpVybiBZlaSPc9qVMihSVJHIz1BODWxdzW2maX/AGjf21mlnbWUlzNI2W+RFVmcgISSBngAnk/j8/fs+Ne6p8W9R1q9jgmTXtIuNSihllLmKMXohVCxXqvlsBgY246dB6d8bbyXSPhHrV1BZWReSw8gl8tlZniiZsAD5gJCRzwT3xgtR1f9foR7dTi2ntf/ANufc0fhHrV14v8AAuh61qGnaatzdRT71iBVDsmMYOCGOcKO56np0rwj9oSymm8E/C5bazVpDpU0p8hSzMqQW7MzADgBQWJ5wAT2r0j9mfSP7M0DxBpnl2959j1y8tvMlGzfsSBd2MNj1xk9T+PJ3lkmva5FY29vHfXWn/Dd5be1glZzFdSR7M+Wo/1rRyL8pHIKH+6aGveRnUbdC0nrdf8At3me/wCivBqdhpV7Z2tnNbXdmLiJ2yvmIwQhiCmQcEcH1NfNNpqFp/w1Ra6q0QbS5Lz+zEmeFxE90LRYGjzs+8JGUHjA3A5wd1ep6H4v07w98CdD8TjTob+1stJihMaHY0kqtHAQdycYkyCeeMkZ4z5b4i8P33hO7+Hd94qk06K71TxNJrN2FfbFbCR7YtGzHI2qFJJyQMnqBktuyCT9old+f3X8z6Ll1LTrHWNA0u7is1vtVhl+yRMrHzzGiu5JCEKQvPJ5ycH10rW23fZP9Cs23QFvmb733eT8vXn36nmvmzxoupa18UtY8UaH9inj8CxWTzW1vN5ZurcBpLhWk5G8EyKy4+7kYJGG9l1HXo734WXXiXQY7MZ0O4vbeXKSMjrFnLDaV3owwVORkMCeKbRXtbuSb7/r/ePCdB0rT9D+F/w48aJY+Tcx66ZtT1KMyOxtjO0cnm7QcJhI1xgj5iAMuwb2z4y3y6N8J9bu2062lEmmtb8Pg5mMcIkPy9V8zdjvyMjrXn/izR4tI/ZPtIYIkKSaba3ZkdwzlpbmCVuijoZCAOw7nv1v7Q0O34L6s32a3TMFu29T8x/0mDk/L159e559SxEHam/T/wCS8zlvg94Mk8GfGSfSpLaxlF14YgvNqzO6hg0UcjZZc5aVZGA6AMOnQL+1YA/gnw7YQWym9nuGu1SBGdnihgYyu2FwAocE5PQk9ATXU6vbTaZ8dfBN7HBYyxa5pFzpskMin5RCPtHmbscMSyjoeAfUEYFpox+JvxF8WN+7XT9I0yTQ7CXy5ViW5liKTy84DyIXZSMYIKHPCsS1m2JtqLpp7O3y1fc9Z8KXH9s6BoOp/wBm2cf27To7ry2k3Y3pG3J2ckbsdO5r5d+HV3bXHx/8Naiqw/2dJDHYJLODHDJcR6ckTxhmXBcSFRgA5LLjO4E+7fBTUxe/CTw3qWpW2mQw29hLHJK7eWgjgfy/MckHBCoCTnHLHjpXi+h6fLo3wT8L+KpoRd2UXidddvEj2hkhSQQFcMfmyyrj/rp0wCam2txznzwSb13+6/n/AF+X0Z4m1S38NeFrnW7yysHhs7CS42SzCPzmAXapYqcMzEKOvLfnwvwb8XSePjouo3WmWKXsFrqFrcBV2RuyyWbBlB3H7jp1PXd0GMx/Eexn8ZeNvCngSG0jjsPs661q7q5QT2yttWMlSp+ZwQcAkFkYfdNUPhtp8+lfHrxPo7QGWxls31e2S6UAM1wbcyur7PmXeu0DkDaRnO4kmrr+u5p7T33rpqt+tn5nDfEqxRPEnxH16FUh1PQZNEvrOVVRtrlETkMpyDvDFeASq5yBg/R+q3cGi6FNq13p8EtvZafLeSqhBeRY1DE4K43YHGT36ivCNE0mw1/4VfFm4RIJEk1PUbpbuBl3SLAIp48NtO5M9Bno74Izmus+Iup34/ZwTVStst9eaLamacIpMnnGBZCV2YBIkYcdNxIIIFW+xCnyt+d3/wCleZkfDHx/qHhzRvDmn/EfQ1tLK8hjGm60yILWSGRcxCZ1BCOAuM9cMC4XBZvbdNSK7t9PntrawuIJ7bzY5FcMsqkIQ+QpB4OR169fXA8GaLaXvgDwvY3uk6deWj6Rb7orlQ6ybUiILAoQSDg968f8Pa0vhD4VfELRZhcfaNAluba03R+XcQw3LKttLu2qGy7s4YHODkYG0GUrq6KvOHuzd9+vXXzPTfDHibQPFfjOwTw/PpeoPZWF7FcKjkEMJLT5iCnIPOGGVPzYY4NY3xw8Sa14d0DQrPwjZxP4h1VisCQWn2qV4o0DyOqbCu4fKDkNwzY6ZHEa/pFv8NB8JdXTQrG0azic61KImnJWVYY5pJmQEna0zbeWALKFGMKe1son8T/H2GMWo+xeE9KDFSY1R7q5QfMTtLMDEw47NH15+ZJK7YpVajhro/X18/U7P4d6tH4p8IeH9YjtLCRruy3S7Qyr5qlVkGGXPDhgOv1PU8V8GfiBp3ibVIfCllpMLS6TpMLG6Z/knZViSQEFAVZXbaPvA/Mc4xmr8GbuPwvZ+LfDmswj7L4Wllu1luQjbbGVfNjYmNSWbAdzxn58cY2jkvh58NdXb4feGfFnhmGGLxfFLdamsV/Euy9jciPyTlQQrRqGQlsfvWIK7gyjjqEqslFRvru9e179fM9j+Ieqr4a+H+p6v5dpbSwabIYJinmHzmCrExXYQTvZBzkcnJAzXmf7O2q6pqOqJpHiZJrjXNNgvGeHUo3SZIJWs2jLsyZbJ8wjJJwew25i8eeMbPx78M7LR9Ksbez1rVdSttEura4cpLYXBkVt0o2ZKkxEAgchm7qy1Y+K/wAPmTU9U8TaPq+paVqc+h3GoyG2utqMLVbcBdqqrYZSc/MfmIPQYJNaf13K5258yfR9e/N5nT/F/WvEOnW3hrRPBFhat4j1vzPIcrE37uJFkkP73CB8YxncMF+hwa6b4Za2PF/gzQdaGm2iPdWriVG+UGRHEbnGG43K2MknB55rzr4Y6lD46+LkGtR6bp9z/Z3ha1guZAUMUd3KRITH95gwV5EPcFXUn1TT7mD4NeLL2PXbONfBGvObyxulQPHZ3BQGSN1SPcAdoCgAgADGf3hFWM1Vk5OTen/D+YjfEr/hC9S8H6Zqmi20+gP4btLq6uoo2aS2LsIxNJgEbAQoIxnL8EnCnv8Axz4lg8L/AA9uPEtvZWN5HHYCW3ZSJEmaQxrG7YxldzqThvuk4PTPmvwL07TvFOueLrhtOgvdNudKsNMMzq0asVtUjuI0k25zkLu2+qnP3Sewt/gd4Cf7LnwxC2+Euc6ldDd93k/NweenvUwXuo0qTnzSad1d9fXzD4aeJJPF+q6bLe6Ja2mp6fb6hp19CzgobiJ7PeykA8fMMZJ6kZOMtzR+Jdwnx1stBjhsW8NIsWlzv5YlRryRCyN5iplJC4ERU7gNjk45K0/EXhnxf4d+J2ran4E0KxvpvEOj74CWhjW1kVoVlk2uQHfOG5GC02Tu2sDu6/8ACuKx+DEWiaLGzapp0D6rbXkAYXE10hD7gqAEsQTGoJYqGXklQSKOrJnOTSint5+cvPW/kWPizpsniHxD8O/CckdvDpmrzzXN4Ed1a5S3jWTy2K7cBgT6kHaR05pfsx37XHhWXw9d2Vt9t0eRyI5YnjZ7eYiWKViVIO4tJtI/hx7FovhHJe+P/HFp43uvDtrb2Fvoa6ZC9xgC4ulcGWaIbWIUFnTOTwcZJ3Bc+0ttb8H+IvC3iDw94Tl8QW+v+HrW0uLS2ncKLiMRBZ5SUZIxsKqCcD75JHJI/isTz6Oq+9vk7+fc5TxzEusaF8XtdGnoLJbqwsoJZdhZbi2eKKZlAyQSJOvGVkPPUV6v8TfEEfh7QovEFnDayY8P3bWtxBsly8klmkUuCu1gGkVu4Iz16Gn4e8FaloXwO1bT7yxS68Qajpd/d3JSV55ZriVPl7HMgXYuFyCwJBOcni4bex8eXPwV0TT4ra4jtLD7bqCm2d0McIRCJcoBtaSCWLPzDJHUEbnPXQFV5Hfun+vn5mt8CfDFz4I+IN74eu7SCd9U0C01ciacMYWU+XIhwmCfMeTGMgKByxJNcb8TYU1+9+IHihDOf+EcSwsNLuYg0KQzLNGJ8MFUvIrs3UnHmZ5Gw16b8ZIH8OXng/x9BplnNHorlL9VRS81rMFjLEkrllLnavzfNLnoDl/wW8Mf218ObqbxPplrdJ4oubvU5rWZGiCLIyKNuQWx8gdGBzhwQeATRNrXp9r2/Hz7m1c3x0L4KQapGthaz2/hvzYZ5Sv+t8hBGSGXBbeVAU5yWx3586+AmlReEvHVnpIktLiDxJ4ZtdZSO7YBxN3jQ4w3BmbG3IUdflJPK6Trdzr3wPt/B/8AoU+pXOuRaBbzSSkSRI0iSxSSjDHblHjXGBtGB9wg+0/E7wtreoR+G9f8IW1q/iHRd01vbPsMd4knlpKsm/aB8pzndnG7HJBERXuqxdZuUnPZr/N36/15HF/G/wAOT+OvGHh3wxpmnM17ZaJeao7RSxxhw6hIQS3czRqGHo/UcsO58JeM7OX4SaZ4w1e2gMMOmu900pRHnliYRuQMbdzyKQgzzvA4ziuc+F/hzX1+KOoeJfFOj2Vjea1ZTLDY+Ykgjhh+yqr71LAlgwB4HKk4AIAitPgrdHxXap9usm8ENef24NJaJNxuQFHlk+XjycEfLyNuVxn56e7aE+aLdRPe/X1XfyMfwpq3jDRPEnhvxP4k8q60Dxpdi1i01mWQWSyBfsrA8BSQcsVU5UEtlyAL/wAD/L1z4i6te7rW8GlaBpunW6KyeUqvEjyAkKSXEqsDnkEsD0GO5+Kvg6bxj8PbrSrKys/t72v2i1YhSxlQowwSAFZhlM54EjZOMg1fgV4Q/wCEb8C6WHWK8uNVjOqTGYgAPKkXygBTgKAo6nJ3HgEAJrX7y7tXjJ363v25vP5neWttu+yf6FZtugLfM33vu8n5evPv1PNTWdpus4G/s+xfKKdzNyeOp+TrUNrbbvsn+hWbboC3zN977vJ+Xrz79TzU1nabrOBv7PsXyinczcnjqfk605L+v6RVWWm/4+b/ALxxvgrwpotx4W8NyzeGtCmll0uKR3kt0LSEpGSzEofm59+p59eL+OXh3TY/Bmj6TpXh7RbXUNfvbbTLe7SJYzC7urCRisef4Npx2c9cYPpHgS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmuC8WgeKvi34K8L2cUTRaOv8AbupiGWMAFQvkByQWB3EbkxyswP8AtCYJKKdv6+4vE1X7yv3W/r/e/r8srwn4WtIf2htfs7zQNMewu9EhvbS3ljjMOweTGXC7TtbeJB0B+8ehBOhqPhzTdR+NnhDSbPw5ocVtpujz6rdgxqFu0l/cKrKI8FlcBuc/ePQjmL4pXUvgnxt4a8bxaeLuyTTJLXVbdHj+a1EsQVwGXO/zbhCcHJwoyBuNaXhGKXVvj34muJbeyKaPo1pp8cOwjzFmCz+Yzc/MDuHToR6ZL5VrZGNSc2nG/X9W+54X4G02XS/iHof9oaVY6jo2layfDX72ExpeSzPOPMfIZWZN4JHUKIh/tV9F+HtE8N2XgPRtW1bw9oRgh0Vbu5nktVdiqxIzyNiMktjJ7k5P4898dNLj0fwFZa/pVjplpNpGo2+tuiw/LeS+YkeZQoXJJkBJySQCM96wNE1nxJ8QfDreFvBOjaLFptrpA0691bUjKEmkaCJXSLagIlQs+Thx0OQCu4lFOS07lRm6MJJN/wBKS6PyObbQI9L/AGfvBfiW40KwMulX6andrPH5ct9b/amVUJKHKsJY8ZyCnPPAPTP4b0jxR8ZfEHh2x0bTbQW/hM2hkNsmyK4lKMtwigcuEmAzweCM4wT6Vd+DDd/DGLwrHb6dPM2hmyinnGFaRYkVJmG07SG2sMZIPQ5HPmP7Mnh6SCDS9au4re7udXs73Y8szsRBBLawxowIIBUrJjH8LAZ4ABLRbGavpTk+nftfz/ryOY+DXivStO0eeLx9o2gS28WltqGmTTWtrHJcwxuYmiBwN8haIhQw3Md5LEYqKTwxd6DZ6T8V9X0ewmsri8FzPo4jikij02VUjiOwBF8wBxj72S6MwBV8+u+I/g5omvaP4S0u0s7eysdKmNz5fmyuZ4GZWmiLZDKXJHzZYr2xXoa2EV3BBBcabYTwT2zLJHLhllUhQdwKEHg9Oep/F2S6BaduWctvPrr59Dwb4b6bpHjT4jaP9k0vTLjS/DmgQG52JB5VxezRgEyEIWk+UnIP3XjPI53Y3xjtdP8Ah/4h1O6bQLWfTfFGgm3tUCQ7Le8ULGZU+TdHtjYOQPvM/Xuvuvw20i0svB3h1bHR9MgWfTop5BGoTzXMcWZHwnLnjk5PvS+IPBdh4nuPDU97aRJPpc6ahBJC6q0jIVO1yYydhOMqOuBzxUwS5UaVuZ83va3vv6rv2PBPjV4dbwnonw3g0zQdKfVZbCfT5TaW+9rqZ4Iog+Aqs0gZ2ZDyQ5z1619LWHVb7wV4Ev8Aw/YyeLNM19RfP9mSMXllEN++RmRdytGeAdxcRljywDe8614bsNc8X+Ev7S0u1n+x2lxf2/754/3ySWu122gZxuPynIOTmtq18OaW2q2mqf2Bozam0BP2toV85vlVcl9mc7TjqeCRTWrfkRKm4K0Xo/P1XfyPJPAWjaFovjj4k2+p6bplzo2lpBqn+mWscn2dZofNl2kRltoAGEAOAOMkktc/Z88A6aPBFhrGr6Hb3up6uklxKdSTdhFk2x7FZCFUrhgRndvznG0DmviDfS+E/EXxLFxYW11Hrnhq1uoSspBhUlLLJBT726Rn4PQYzk8ez/DqyMfgfwlG1lZuw0e3zlvvYij5Py9f8TTaVylUk5Oz0V+vXXz7HztZ6dZaj8E/C2hwadp1vrN/r39gX15NZn7TbSNOZOSQp3KvljqflZl4PTuvj14Zs4fBkh0nw/p8Uo0iW4LWduofCXNkWkIVByqF8nsrPzjOeQ8Pv/a/jXT/AA1aCza8fx7e6rJ5s2GWK3VH2soUnDjzApPGVI9SPetT0m31TXtLsL3TrSa1vNEvopUMhQyIzWobJC5BwTyDnk80ppJfP9R05aShfZNb+UvM4j4C+DrW58Gxavrnh/SJ7nWri51JIbizCiCNmRVRQysdmF3r2xJ+J86gFnoPwe8caPc6NpM+ueHpZLIXFzYFJnt7iZFjuCSPvESSFCG4AU8jG76V0XSoLDT9KsrPTrNbWCzWKJGcn5FCAZJUnIGOuep59fKtX+FV1rvxct9RniU+Gbm3tdTu4naJ0ubq3BiSIqV3KpRgzAhg2WGckbasuqJm5RitddVv3v5kuq+DtEk+AyyTaDpRuI/DBuRcxxiOVpI4EcSFlUHduAOM85IJIJzzXi3w3pdz8PfhEkuj2CHVb3S4LuSEeXJdJJEN4kdVDcnknJOeeor06y0SfW/hJZaXaW1ilxf+HPs8UkjEAM9uih2whIwW7Z6n8fLo9TXXvA3wRgttORbyTVrfbBGGkMsVmxilkchMAAAMc5wGPUAmogrpMdaXJNxT0s1v5vzNH4u2Wj+GfF/wvvhovh+3spbqWC6WaBFhkjkESM8vygDYrMwJyAee3Ol+z74X0/U/BKa3qWi6Jezazd3d6sclqu23XzFj8tcq3ygxkgdg5HbJzP2oNHivPCOn3csSRPYWUl3GYXA8xjPaRfONvPEzHAPXvxg+ueDNGl0vwx4c065s7CSe10yKGRlYlXZEjUtymevTjvQluVJtVLp9G9+uq79kfPNsmg+FvCXxR0PVNEtW1DTmmls/NEcssdtdCKO3aNiS2ELox5yvmf3iRXoN18No/E/wU0bTNJ0nQrPWrvSLRlvJIwrbl8hnZnWMtuIDDjOdx5rrvEXw08M+Lr+wvdf0K3u7pbMRK4vJocoCCMhMDOXb169eBWn4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmm/i27is7Su9tFr097z8jzb4U+Ar2fxfrOueMvBWk2X2uzto7O1aSKWBdqKJmRF3BdzKrcjI3kZPzE1vGlh4f8ABvxS8J6tqmneHodB1LSLm1uYbi1Xy4/JXzvOAC8yMWRANrE8gZLDHtVrbbvsn+hWbboC3zN977vJ+Xrz79TzXg37VWjTXnhjQ7uGO1hjsLeW7lIY7pFMltF/d+9umU8npu59SSS6BK/K1zee/a/ZnRfBLwVpepfCTQYtb8NadNNeWt0ZHuYvLmkjeZtrb9m4fIy7WB6EEEcV5n4bs9J1TwF8JbKHTtPvtXufEBFyiQiWWWCKZjIs5CnCrHJESGJ+Qg4wK+k/Cui/2ToGg6Z9ns7j7Jp0cHmN8vm7EjXeRtOCfTJ6nn18E+GWlahcftB6hpl7Baxro91qOtojjc063SxIoLAkAbHjccZB3A8nh26mU3KMUr9Lfn5/1+Xr/grwpotx4W8NyzeGtCmll0uKR3kt0LSEpGSzEofm59+p59fGPFHgI6h8brfw7b6RYnT9W+wavIIC0aQ2cMbxzRuUTKeYynkHG4pzk5HvfgS23eEPC/8AoVm27SoW+Zvvfu4+T8vXn36nmtC10m1a/s77+yNNa9azMX2hlHmNHlTgtszjJzjkZJqYK0Vp/X3HTiHKTa5ur6/4vM4rxD4E0nV7m10m30TRbQ3+hXyLMtsnySE2ypNgIPnTeSOc8nBFY/wM+F66B4RgTxToOk3WqXkktyyXUUcjRJ8iqm8BwRhdwwePMI4IOe9+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5oS3X9begVNZKd9Un185f3v6/L5u+L/haTSvGkdt4a8NQNP4q0RbKyS3jjkQ3SzRmWTY3EREHBcABd5bOdzD2LwJ4Q0N/CHhcyeGtDnkbSoWZ5bdC0h8uPLMfL+9z79TzXX2ttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/+hWbbtKhb5m+9+7j5Py9effqeaGvet6/1sJe7zS5vx/xf3jEl+Fnhi98TaHrZ0HT457W3fNuioLe6BUAGWMxkFl3kgjBzjJO0Cpx4U0X/AISnQ4h4a0IxSaXdSMht02uQ9qAzDZ94bjjr948+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U80VFp/X+RUXyuTT3v18pf3jF8EfC3wz4b0u1s7fQrC/MiPM9xqIWaWUkr1JjwABgBQMdT1JJ2rfwdoEi2qt4V8Pur25yGtY/nHy8n93159+prYtbbd9k/0KzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmqaX9f8MTzcseWLstev8Ai/vHI+BvCOhSeE/DTt4Y0CR5NLikZnto8yEpGSzfu/vZOe/U8+uva+D9BP2P/ilvD7boCfmto/m+5yf3fXn36mk8CW27wh4X/wBCs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNTGKcU7f19xdSbTaT79f8AF/e/r8uTHhTRf+Ep0OIeGtCMUml3UjIbdNrkPagMw2feG446/ePPrq2vg/QT9j/4pbw+26An5raP5vucn93159+ppPs27xfoP+hWbbtKu2+ZvvfvLTk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqeaSirvT+reg51JW+Lv1/wAX97+vyxrHwZ4eRLNI/Cnh7aYCQPssYDfd5P7vrz79TWZ4K8KaLceFvDcs3hrQppZdLikd5LdC0hKRksxKH5uffqefXrLW23fZP9Cs23QFvmb733eT8vXn36nmsfwJbbvCHhf/AEKzbdpULfM33v3cfJ+Xrz79TzTlFc23f+thc7UWk/x/xf3v6/JbXwfoJ+x/8Ut4fbdAT81tH833OT+768+/U15h8OPg5Z+EfHSG8az16z1DTriS2t76AH7OqSwEZJDBmxJjIUd+mcV7Na2277J/oVm26At8zfe+7yfl68+/U81j/Zt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzRNWWn9fgJvmldva/X/ABf3v6/JbXwfoJ+x/wDFLeH23QE/NbR/N9zk/u+vPv1NFr4P0E/Y/wDilvD7boCfmto/m+5yf3fXn36mte1tt32T/QrNt0Bb5m+993k/L159+p5otbbd9k/0KzbdAW+Zvvfd5Py9effqeapxXb+vuCVWWvvd+v8Ai/vf1+XlvgT4S+HJrvQ/FN1psV5dXWlQP9kuHU2ocQxKZPLEfLHkncWG5i3UA13dr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqaTwJbbvCHhf/QrNt2lQt8zfe/dx8n5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzUxV4q/9fgE3yylyu12+v+L+9/X5cmPCmi/8JTocQ8NaEYpNLupGQ26bXIe1AZhs+8Nxx1+8efXVtfB+gn7H/wAUt4fbdAT81tH833OT+768+/U0n2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNJRV3p/VvQqdSVvi79f8X97+vyyLXwfoJ+x/wDFLeH23QE/NbR/N9zk/u+vPv1NZXgrwpotx4W8NyzeGtCmll0uKR3kt0LSEpGSzEofm59+p59estbbd9k/0KzbdAW+Zvvfd5Py9effqeax/Altu8IeF/8AQrNt2lQt8zfe/dx8n5evPv1PNDiubbv/AFsDqS5X734/4v739fktr4P0E/Y/+KW8PtugJ+a2j+b7nJ/d9effqamsvB2gtZwH/hFPDz5jU7mto8njqf3daNrbbvsn+hWbboC3zN977vJ+Xrz79TzU1nabrOBv7PsXyinczcnjqfk61Uort/X3GdWrK3xfj5v+8cb4KTWv+EW8NiHQtCliOlxFGk1B1ZxsjwzAW5w3PTJ6nn1fo+h39nrE+qW3hnQRfapBG11I2rzMJvLVVQ7TblVIBP3Rzk5zWj4Ett3hDwv/AKFZtu0qFvmb737uPk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqeamC91f1+hpVmuZ/Pr/i/vf1+XkXxe0vUtW8M3MF/pWmW6r4fvbrfb37FiIntZdxzbjnKKNv8QZvmXgnG/Zum13XYde8TTWun6pf6hcC2ne7uRbriCKPYRHHAwziXBOefQEEt6rqek2+qa9pdhe6daTWt5ol9FKhkKGRGa1DZIXIOCeQc8nmsT4E+D7nwr4C0uy1LSbaDU5/PubpJJxJvYyAKxI3KP3YjAAOOucHOWl8S/r8jKrL94n0s+vnL+9+pD8S9E1zxD8OtT099C03MmnNOn2K/ked3jKSLtX7N8zFlA2553EZGc1T+CPhzWPD3gLRo4tG0W6k1CFtRlmn1GVWlMuxlLKYG2sqbFwCRkE9Sc+nWttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/wDoVm27SoW+Zvvfu4+T8vXn36nmm73t/X5FSs259tN/8X97+vyW1GvN9j/4p/w+26At82pSfN93k/6N159+prKCa03inQy2haE0p0u6KqdQfa432uWY/Z+GHGBg53HkY56y1tt32T/QrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmpmtP67+hamrv59f8X97+vyW1GvN9j/4p/w+26At82pSfN93k/6N159+potRrzfY/wDin/D7boC3zalJ833eT/o3Xn36mte1tt32T/QrNt0Bb5m+993k/L159+p5otbbd9k/0KzbdAW+Zvvfd5Py9effqeatr+v6RMprX59f8X97+vy5PwUmtf8ACLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz66tqNeb7H/xT/h9t0Bb5tSk+b7vJ/0brz79TSeBLbd4Q8L/AOhWbbtKhb5m+9+7j5Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmogvdX9foVVmuaXz6/4v739flyYTWm8U6GW0LQmlOl3RVTqD7XG+1yzH7Pww4wMHO48jHOrajXm+x/8U/4fbdAW+bUpPm+7yf8ARuvPv1NJ9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzQlq/wCunoE5q339f8X97+vy+ZPjbY6xe/FDwvp95YQWVtr9jaaY5tpiyTqbveR5rQjY4byycKxAK5yGwfb/AAUmtf8ACLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz6t8QeDZ9c8beBNXFppT2WkJdTTxTklpi8aCNgNhG5XAbk8EZHNa3gS23eEPC/8AoVm27SoW+Zvvfu4+T8vXn36nmnJe8vn/AFsZQdvaN9+/lL+8eA6bbatc/tX+ZDpNnNdQwLLNAJ3NuimwVdzyeUSASy8lPvMB3zXtQTWm8U6GW0LQmlOl3RVTqD7XG+1yzH7Pww4wMHO48jHLrTwpeH4pW3iXyNOewfw//Z4hZzvMgnEm8jZjoQOuc1pfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzRUWn3f1sFJ8rn5t9fJ/3hbUa832P/in/D7boC3zalJ833eT/o3Xn36mi1GvN9j/AOKf8PtugLfNqUnzfd5P+jdeffqa17W23fZP9Cs23QFvmb733eT8vXn36nmi1tt32T/QrNt0Bb5m+993k/L159+p5qmv6/pFymtfn1/xf3v6/Lk/BSa1/wAIt4bEOhaFLEdLiKNJqDqzjZHhmAtzhuemT1PPr4t8NNL8R2/xL0bw1FokNyvhKe+n33FwixLbXUKmJXlWMljklx8pY78bVCnb774Ett3hDwv/AKFZtu0qFvmb737uPk/L159+p5rYtbbd9k/0KzbdAW+Zvvfd5Py9effqeamC91f1+hOISnJ+TfXzb/m8v66cmE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxzq2o15vsf/FP+H23QFvm1KT5vu8n/AEbrz79TSfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U80ktX/XT0NJzVvv6/4v739flkWo15vsf/FP+H23QFvm1KT5vu8n/RuvPv1NZXgpNa/4Rbw2IdC0KWI6XEUaTUHVnGyPDMBbnDc9MnqefXrLW23fZP8AQrNt0Bb5m+993k/L159+p5rH8CW27wh4X/0KzbdpULfM33v3cfJ+Xrz79TzQ1733/wBbA5rlf+f+L+9/X5LajXm+x/8AFP8Ah9t0Bb5tSk+b7vJ/0brz79TWUE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxz1lrbbvsn+hWbboC3zN977vJ+Xrz79TzWP9m3eL9B/wBCs23aVdt8zfe/eWnJ+Xrz79TzRNaf139AU1d/Pr/i/vf1+S2o15vsf/FP+H23QFvm1KT5vu8n/RuvPv1NZuj6Hf2esT6pbeGdBF9qkEbXUjavMwm8tVVDtNuVUgE/dHOTnNdTa2277J/oVm26At8zfe+7yfl68+/U80Wttu+yf6FZtugLfM33vu8n5evPv1PNXZ/1/wAMTKa1+fX/ABf3jk/BSa1/wi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+urajXm+x/8U/4fbdAW+bUpPm+7yf8ARuvPv1NJ4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/AEKzbdAW+Zvvfd5Py9effqeaiC91f1+hVWa5pfPr/i/vf1+XJhNabxToZbQtCaU6XdFVOoPtcb7XLMfs/DDjAwc7jyMc6tqNeb7H/wAU/wCH23QFvm1KT5vu8n/RuvPv1NJ9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzQlq/66egTmrff1/xf3v6/LItRrzfY/8Ain/D7boC3zalJ833eT/o3Xn36msrwUmtf8It4bEOhaFLEdLiKNJqDqzjZHhmAtzhuemT1PPr1lrbbvsn+hWbboC3zN977vJ+Xrz79TzWP4Ett3hDwv8A6FZtu0qFvmb737uPk/L159+p5oa977/62BzXK/8AP/F/e/r8ltRrzfY/+Kf8PtugLfNqUnzfd5P+jdeffqaygmtN4p0MtoWhNKdLuiqnUH2uN9rlmP2fhhxgYOdx5GOestbbd9k/0KzbdAW+Zvvfd5Py9effqeax/s27xfoP+hWbbtKu2+ZvvfvLTk/L159+p5omtP67+gKau/n1/wAX97+vyW1GvN9j/wCKf8PtugLfNqUnzfd5P+jdeffqaLUa832P/in/AA+26At82pSfN93k/wCjdeffqa17W23fZP8AQrNt0Bb5m+993k/L159+p5otbbd9k/0KzbdAW+Zvvfd5Py9effqeatr+v6RMprX59f8AF/e/r8uT8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz66tqNeb7H/wAU/wCH23QFvm1KT5vu8n/RuvPv1NJ4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5qIL3V/X6FVZrml8+v8Ai/vf1+XJhNabxToZbQtCaU6XdFVOoPtcb7XLMfs/DDjAwc7jyMc6tqNeb7H/AMU/4fbdAW+bUpPm+7yf9G68+/U0n2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNCWr/rp6BOat9/X/F/e/r8si1GvN9j/AOKf8PtugLfNqUnzfd5P+jdeffqayvBSa1/wi3hsQ6FoUsR0uIo0moOrONkeGYC3OG56ZPU8+vWWttu+yf6FZtugLfM33vu8n5evPv1PNY/gS23eEPC/+hWbbtKhb5m+9+7j5Py9effqeaGve+/+tgc1yv8Az/xf3v6/JbUa832P/in/AA+26At82pSfN93k/wCjdeffqaygmtN4p0MtoWhNKdLuiqnUH2uN9rlmP2fhhxgYOdx5GOestbbd9k/0KzbdAW+Zvvfd5Py9effqeax/s27xfoP+hWbbtKu2+ZvvfvLTk/L159+p5omtP67+gKau/n1/xf3v6/JbUa832P8A4p/w+26At82pSfN93k/6N159+potRrzfY/8Ain/D7boC3zalJ833eT/o3Xn36mte1tt32T/QrNt0Bb5m+993k/L159+p5otbbd9k/wBCs23QFvmb733eT8vXn36nmra/r+kTKa1+fX/F/e/r8uT8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz66tqNeb7H/AMU/4fbdAW+bUpPm+7yf9G68+/U0ngS23eEPC/8AoVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5qIL3V/X6FVZrml8+v+L+9/X5cmE1pvFOhltC0JpTpd0VU6g+1xvtcsx+z8MOMDBzuPIxzq2o15vsf/FP+H23QFvm1KT5vu8n/RuvPv1NJ9m3eL9B/wBCs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U80Jav+unoE5q339f8AF/e/r8si1GvN9j/4p/w+26At82pSfN93k/6N159+prK8FJrX/CLeGxDoWhSxHS4ijSag6s42R4ZgLc4bnpk9Tz69Za2277J/oVm26At8zfe+7yfl68+/U81j+BLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5oa977/wCtgc1yv/P/ABf3v6/JbUa832P/AIp/w+26At82pSfN93k/6N159+pqazTXms4G/wCEd8PNmNTubUpMnjqf9GrRtbbd9k/0KzbdAW+Zvvfd5Py9effqeams7TdZwN/Z9i+UU7mbk8dT8nWqkv6/pGdWorf8Hzf94wfAltu8IeF/9Cs23aVC3zN9793Hyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNfDtFcKxllbl/r7j6GWSOTb9pv5Pz/veZ9lfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U818O0ULGWv7u/9dglkjf/AC8/B+f97zPuK1tt32T/AEKzbdAW+Zvvfd5Py9effqeax/Altu8IeF/9Cs23aVC3zN9793Hyfl68+/U818a0UPGXd+X+vuB5I7Ne0/B+f97zPuK1tt32T/QrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmvjWiiWMv9n+vuD+xH/z879H5/wB7zPuK1tt32T/QrNt0Bb5m+993k/L159+p5otbbd9k/wBCs23QFvmb733eT8vXn36nmvh2iq+u/wB3+vuE8jb/AOXn4Pz/AL3mfZXgS23eEPC/+hWbbtKhb5m+9+7j5Py9effqea2LW23fZP8AQrNt0Bb5m+993k/L159+p5r4doqVjLK3L/X3Dlkjk2/ab+T8/wC95n2V9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXw7RQsZa/u7/wBdglkjf/Lz8H5/3vM+4rW23fZP9Cs23QFvmb733eT8vXn36nmsfwJbbvCHhf8A0KzbdpULfM33v3cfJ+Xrz79TzXxrRQ8Zd35f6+4Hkjs17T8H5/3vM+4rW23fZP8AQrNt0Bb5m+993k/L159+p5rH+zbvF+g/6FZtu0q7b5m+9+8tOT8vXn36nmvjWiiWMv8AZ/r7g/sR/wDPzv0fn/e8z7itbbd9k/0KzbdAW+Zvvfd5Py9effqeaLW23fZP9Cs23QFvmb733eT8vXn36nmvh2iq+u/3f6+4TyNv/l5+D8/73mfZXgS23eEPC/8AoVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/QrNt0Bb5m+993k/L159+p5r4doqVjLK3L/AF9w5ZI5Nv2m/k/P+95n2V9m3eL9B/0KzbdpV23zN9795acn5evPv1PNbFrbbvsn+hWbboC3zN977vJ+Xrz79TzXw7RQsZa/u7/12CWSN/8ALz8H5/3vM+4rW23fZP8AQrNt0Bb5m+993k/L159+p5rH8CW27wh4X/0KzbdpULfM33v3cfJ+Xrz79TzXxrRQ8Zd35f6+4Hkjs17T8H5/3vM+4rW23fZP9Cs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqea+NaKJYy/2f6+4P7Ef/Pzv0fn/AHvM+4rW23fZP9Cs23QFvmb733eT8vXn36nmi1tt32T/AEKzbdAW+Zvvfd5Py9effqea+HaKr67/AHf6+4TyNv8A5efg/P8AveZ9leBLbd4Q8L/6FZtu0qFvmb737uPk/L159+p5rYtbbd9k/wBCs23QFvmb733eT8vXn36nmvh2ipWMsrcv9fcOWSOTb9pv5Pz/AL3mfZX2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNfDtFCxlr+7v/AF2CWSN/8vPwfn/e8z7itbbd9k/0KzbdAW+Zvvfd5Py9effqeax/Altu8IeF/wDQrNt2lQt8zfe/dx8n5evPv1PNfGtFDxl3fl/r7geSOzXtPwfn/e8z7itbbd9k/wBCs23QFvmb733eT8vXn36nmsf7Nu8X6D/oVm27Srtvmb737y05Py9effqea+NaKJYy/wBn+vuD+xH/AM/O/R+f97zPuK1tt32T/QrNt0Bb5m+993k/L159+p5otbbd9k/0KzbdAW+Zvvfd5Py9effqea+HaKr67/d/r7hPI2/+Xn4Pz/veZ9leBLbd4Q8L/wChWbbtKhb5m+9+7j5Py9effqea2LW23fZP9Cs23QFvmb733eT8vXn36nmvh2ipWMsrcv8AX3Dlkjk2/ab+T8/73mfZX2bd4v0H/QrNt2lXbfM33v3lpyfl68+/U81sWttu+yf6FZtugLfM33vu8n5evPv1PNfDtFCxlr+7v/XYJZI3/wAvPwfn/e8z7itbbd9k/wBCs23QFvmb733eT8vXn36nmsfwJbbvCHhf/QrNt2lQt8zfe/dx8n5evPv1PNfGtFDxl3fl/r7geSOzXtPwfn/e8z7itbbd9k/0KzbdAW+Zvvfd5Py9effqeax/s27xfoP+hWbbtKu2+ZvvfvLTk/L159+p5r41ooljL/Z/r7g/sR/8/O/R+f8Ae8z7itbbd9k/0KzbdAW+Zvvfd5Py9effqeaLW23fZP8AQrNt0Bb5m+993k/L159+p5r4doqvrv8Ad/r7hPI2/wDl5+D8/wC95n2V4Ett3hDwv/oVm27SoW+Zvvfu4+T8vXn36nmti1tt32T/AEKzbdAW+Zvvfd5Py9effqea+HaKlYyyty/19w5ZI5Nv2m/k/P8AveZ9lfZt3i/Qf9Cs23aVdt8zfe/eWnJ+Xrz79TzWxa2277J/oVm26At8zfe+7yfl68+/U818O0ULGWv7u/8AXYJZI3/y8/B+f97zPuK1tt32T/QrNt0Bb5m+993k/L159+p5rH8CW27wh4X/ANCs23aVC3zN9793Hyfl68+/U818a0UPGXd+X+vuB5I7Ne0/B+f97zPuK1tt32T/AEKzbdAW+Zvvfd5Py9effqeams7TdZwN/Z9i+UU7mbk8dT8nWvheim8Zf7P9fcTLIpS/5efg/P8AvH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a complete absence of properly formed QRS complexes and no obvious P waves. A recent onset (eg, within minutes) of the arrhythmia is suggested by the coarse morphology of the fibrillatory waves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30455=[""].join("\n");
var outline_f29_47_30455=null;
var title_f29_47_30456="Silicotic nodule pathology";
var content_f29_47_30456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Silicotic nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The central zone of the silicotic nodule is hyalinized with concentrically arranged collagen fibers. The peripheral zone is whorled and becomes less organized toward the edges. This outer zone contains macrophages, lymphocytes, and lesser amounts of loosely formed collagen and is the site of active enlargement and ongoing inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. J Parker.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30456=[""].join("\n");
var outline_f29_47_30456=null;
var title_f29_47_30457="Treatment and prognosis of common variable immunodeficiency";
var content_f29_47_30457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of common variable immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Sam Ahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Lloyd Mayer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Charlotte Cunningham-Rundles, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30457/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30457/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/47/30457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common variable immunodeficiency (CVID) is an immune disorder characterized by impaired B cell differentiation with hypogammaglobulinemia. The disorder is associated with a broad spectrum of clinical manifestations, including recurrent infections, chronic lung disease, gastrointestinal disease, and autoimmune disorders.",
"   </p>",
"   <p>",
"    Immune globulin (IG) replacement therapy has dramatically altered the clinical course of CVID by reducing the burden of recurrent infections and subsequent complications. Management also involves vigilant monitoring for associated problems, such as pulmonary damage, gastrointestinal, autoimmune and granulomatous diseases, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and health maintenance of patients with common variable immunodeficiency will be discussed here. The clinical manifestations, diagnosis, and pathogenesis of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOGLOBULIN REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who meet diagnostic criteria for CVID should receive IG replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impact of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin replacement therapy reduces the number of infections and decreases antibiotic use and hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In one retrospective series of 50 patients treated with IVIG, the annual incidence of pneumonia decreased from 81 percent before treatment, to 35 percent on therapy, and the rate of hospitalization decreased from 89 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/4\">",
"     4",
"    </a>",
"    ]. The effectiveness of IG replacement in hypogammaglobulinemic patients was immediately apparent after this therapy became available, and so randomized controlled trials were never undertaken.",
"   </p>",
"   <p>",
"    Treatment with IG does not entirely eliminate infections in most patients, and the sinopulmonary and gastrointestinal systems, in particular, remain susceptible. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sinusitis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Gastrointestinal infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     On progression of chronic lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin replacement may slow the progression of chronic lung disease in patients with CVID, although this has not been conclusively established. A prospective study of 24 patients receiving standard dose IVIG found a significant improvement in FEV1 and high resolution CT scores in patients with chronic pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal infections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications are relatively unaffected by IG replacement, although the reasons for this are not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     On other complications of CVID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin therapy may exert a protective effect in those with autoimmune disease, although it does not appear to prevent or treat other complications of CVID, including the development of malignancy or granulomatous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy for most patients is to supply sufficient IG so that the level in the blood is at least near the middle of the normal range and the patient experiences a significant decrease in major infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overview of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;IG replacement therapy may be administered either intravenously (IVIG) or subcutaneously (subcutaneous IG). A typical approach is to begin therapy with IVIG. After two or more months on IVIG, the subcutaneous route may be substituted if this is preferred. We occasionally start patients with very poor venous access on subcutaneous IG from the outset. A discussion of the characteristics and safety of various preparations of IVIG, as well as conversion from IVIG to subcutaneous IG, is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"     \"Subcutaneous and intramuscular immune globulin therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intravenous route",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG therapy can be administered in the office, infusion center, or home. Selected patients may also be candidates for self-infusion of IVIG. The placement of indwelling catheters solely for the administration of IVIG is not recommended due to the propensity of CVID patients to develop infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual initial dosing for IVIG is 300 to 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three to four weeks. To initiate therapy, we usually give the patient one-half of this dose in the first infusion, and administer the remaining half two weeks later.",
"   </p>",
"   <p>",
"    The half-life of IG is approximately three weeks, although variability among individuals exists. Steady-state levels are usually achieved after three to six months of therapy, and we measure trough levels of IgG beginning six months after the first dose.",
"   </p>",
"   <p>",
"    Higher doses are required in some patients (eg, 500 to 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per month) to attain satisfactory trough levels of IgG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Indications for higher dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard dosing may not result in control of infections or other desirable outcomes in all patients, particularly those with chronic lung disease, gastrointestinal disease, or refractory sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. One study documented progressive lung changes by high-resolution chest CT (HRCT) of 21 in 22 patients followed over three years, despite maintenance of trough IgG levels of 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher IG doses may be able to provide additional benefit for patients with ongoing lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. One study showed radiographic improvement of chronic lung disease in 4 of 12 CVID patients receiving a dose of 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    compared to no radiographic improvement in any patient receiving a dose of 200",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    In addition, all 6 patients switched to higher dose IVIG in this study showed improvement in FVC and FEV1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/12\">",
"     12",
"    </a>",
"    ]. There are no studies directly comparing 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (or other doses) to 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in order to determine the optimal dose in such patients. Until more data are available, it is our practice to initiate IG therapy at a higher dose of 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in patients who have evidence of chronic lung disease at diagnosis. The goal trough level is the same as that for standard dosing.",
"   </p>",
"   <p>",
"    Very high doses of IVIG (ie, &ge;1",
"    <span class=\"nowrap\">",
"     gram/kg),",
"    </span>",
"    either given as a single dose or repeated every three to four weeks until resolution, may be helpful in patients already on standard therapy who develop autoimmune hematologic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Autoimmune disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trough levels of IgG are usually measured every six months, even after steady-state is achieved. Dosing may need to be adjusted periodically, as patient weight and endogenous production or clearance may change over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Subcutaneous route",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to IVIG for maintenance therapy is subcutaneous IG. This is usually administered weekly or every other week, depending on body weight and IG requirements.",
"   </p>",
"   <p>",
"    Subcutaneous IG is particularly helpful for patients with reactions to IVIG infusion, difficult intravenous access, or rapid IG loss (such as those with rapid catabolism, nephrotic syndrome, or protein losing enteropathy). It can be self-infused at home, which is more convenient for many patients and can improve quality of life. Initial dosing of subcutaneous IG, and conversion of patients from IVIG to subcutaneous IG are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"     \"Subcutaneous and intramuscular immune globulin therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics may be administered prophylactically, as well as for the treatment of acute infections or exacerbations of chronic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prophylactic antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of prophylactic antibiotics for preventing infections in patients with CVID has not been adequately studied. We do not routinely administer prophylactic antibiotics to all patients with CVID, although we do find this approach helpful in CVID patients with ongoing lung disease. The use of antibiotics in this manner is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H18#H18\">",
"     \"Medical management of immune deficiency\", section on 'Prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with known exposures to influenza may be treated with antiviral medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H14#H14\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Patients with low CD4 counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics to prevent infection with Pneumocystis carinii (P. jirovecii) may be given to patients with CVID and CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mcL;",
"    </span>",
"    however, it is not standard as it is in patients with HIV infection. In contrast, prophylactic antibiotics are recommended in CVID patients who require oral glucocorticoids or other immunosuppressive medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) for over one month, regardless of CD4 count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of specific infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are essential for treating acute infections in patients with immune deficiency, and it is our experience that CVID patients typically do not clear common infections without the use of antibiotics. As examples, acute sinusitis or bronchitis is unlikely to clear spontaneously in patients with CVID, unlike in the general population, even in patients receiving IG replacement. Thus, prompt identification and treatment with antibiotics can help prevent chronic infections and infectious complications. It is also important to ensure that the infection has cleared completely at the end of a course of antibiotics, as patients with immunodeficiency sometimes require longer durations of therapy.",
"   </p>",
"   <p>",
"    Antibiotic resistance does not seem to be a prominent problem in patients with CVID, for reasons which are not clear. One study found that the lungs of patients with primary antibody deficiency were persistently colonized with Haemophilus influenzae (identified in approximately two-thirds of patients) and that the isolates remained sensitive to commonly used antibiotics and resistant strains were not found despite repeated treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/15\">",
"     15",
"    </a>",
"    ]. This is consistent with our clinical experience that the same antibiotics continue to be useful, despite prolonged or repeated exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bacterial sinus infections in patients with CVID are commonly caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, similar to in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/14\">",
"     14",
"    </a>",
"    ]. For acute sinusitis, we often use a two to four week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    initially. Alternative options include cephalosporin, macrolide, and (in adults) fluoroquinolone classes of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic sinusitis can be complicated by infections with Staphylococcus aureus, Pseudomonas aeruginosa and anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/14\">",
"     14",
"    </a>",
"    ]. Chronic sinusitis may persist despite IG replacement, possibly because of the multifactorial nature of this condition (ie, chronic infection is just one factor in pathogenesis). The impact of higher dose IG has not been reported. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications for higher dosing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are currently no published studies regarding antibiotic prophylaxis in CVID patients with recurrent sinusitis despite immunoglobulin replacement. We do not routinely recommend daily antibiotics for prophylaxis. Instead, we encourage patients to maintain good nasal hygiene with saline irrigations, and we treat infections as they arise. We also try to avoid surgical treatment of chronic sinusitis, as disease invariably returns. The medical management of chronic rhinosinusitis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary infections that do not clear and continue to cause fever should prompt evaluation for mycoplasma. Mycoplasma infections are usually responsive to macrolide antibiotics. This organism can also infect the bones and joint tissues in patients with CVID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26537?source=see_link\">",
"     \"Microbiology and antibiotic management of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H21#H21\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of bronchiectasis is thought to be driven by a cycle of chronic infection and scarring resulting in increasing susceptibility to infection. Antibiotics play an important role in the treatment and prevention of this condition. Inhaled glucocorticoids may reduce cough and dyspnea, although they should be used sparingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Antiinflammatory medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute exacerbations of bronchiectasis may be precipitated by bacterial infection, such as H. influenzae, S. pneumoniae, and Mycoplasma species, a commonly missed but important organism in CVID. Although prompt sputum culture to direct therapy should be performed when possible, empiric treatment should include coverage for these organisms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     Amoxicillin-clavulanate",
"    </a>",
"    , third generation cephalosporins, and fluoroquinolones (except",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) for at least 14 days are frequently used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Treatment of infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with bronchiectasis may also have chronic lung infections that require long-term treatment with broad-spectrum antibiotics. Prophylactic antibiotic therapy chosen for efficacy against H. influenzae and mycoplasma may help some patients with frequent exacerbations and declining lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disease progression may be insidious and can be monitored with pulmonary function testing and a CT scan of the lungs at baseline and possibly every one to two years thereafter if additional therapeutic interventions (eg, a change in antibiotic treatments or an increase in IG dose) are contemplated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, high resolution CT examinations should probably not be performed at regular intervals unless the information these tests provide is essential. Radiation exposure should be limited to that which is absolutely necessary, as cellular radiosensitivity has been demonstrated in patients with CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who progress to severe bronchiectasis, surgical intervention is required in rare cases to remove the significantly diseased segments of lung tissue. This should be reserved for patients in whom intensive antibiotic and IG therapy, over a period of months to years, has failed.",
"   </p>",
"   <p>",
"    Finally, lung transplantation has been performed with varying success in patients with antibody deficiency, with somewhat worse outcomes than those seen in patients with cystic fibrosis, although there is little published data for analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Gastrointestinal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic or recurrent diarrhea, stool cultures should be examined for ova and parasites, because giardia, campylobacter, salmonella, and cryptosporidia are seen with greater frequency in patients with CVID. Acute or chronic giardiasis is generally responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no specific antibiotic prophylaxis that is utilized to prevent gastrointestinal infections in patients with CVID and the impact of IG therapy on the gastrointestinal tract appears to be minimal, as reviewed previously. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Impact of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES TO AVOID INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of IG replacement, the quality of life for most patients with CVID has dramatically improved. As a result, many patients are able to travel and participate in other activities that might not have been possible in the past for people with immunodeficiencies. In general, we do not advocate restricting foreign travel, unless the travel is to a remote area with no access to healthcare. Patients should bring antibiotics that they might need and consume bottled water from a clean source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     VACCINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of vaccinating patients with CVID has not been studied extensively. By definition, patients with CVID have impaired responses to vaccination, although vaccination might reinforce T cell immunity to infectious agents, in addition to inducing the formation of specific antibodies. The former mechanism may be preserved in some patients with CVID, as there is a range of immunologic capacity in this disorder.",
"   </p>",
"   <p>",
"    There are no reports of CVID patients being affected adversely by vaccination with either live or other types of vaccines, in contrast to patients with severe cellular immune defects. However, the safety of live vaccines in a patient with CVID and significantly impaired T cell function has not been examined, although we know of no reports of adverse outcomes. Issues related to vaccination include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family members and household contacts of patients with CVID may receive live vaccines.",
"     </li>",
"     <li>",
"      Patients with CVID who are planning to travel should receive the appropriate vaccines to prevent infectious diseases endemic to that area.",
"     </li>",
"     <li>",
"      We routinely administer influenza vaccine to patients with CVID, although at least one study showed that some CVID patients respond only partially [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, we treat patients with a known exposure to influenza with antiviral agents. Patients receiving IG replacement may be partially protected from influenza due to the presence of anti-influenza antibodies in the immunoglobulin preparation, although this has not been formally documented. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"       \"Medical management of immune deficiency\", section on 'Vaccination'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     THERAPY FOR NON-INFECTIOUS DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-infectious disorders in patients with CVID include restrictive and obstructive pulmonary conditions, inflammatory bowel disease, autoimmune conditions, and granulomatous or lymphoid infiltrations of various organ systems.",
"   </p>",
"   <p>",
"    Several of these conditions necessitate the administration of chronic immunosuppressive therapy, and a higher incidence of complications (including overwhelming infection and neoplastic disease) has been reported in patients with CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, patients should be carefully monitored for the specific complications associated with the therapy in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications are common in patients with CVID. Bronchiectasis, bronchospasm, restrictive and obstructive pulmonary disease, and non-sarcoid granulomatous disease are among the most common. Although the literature is inconclusive, some improvement or stabilization of disease may be achieved with higher doses of IVIG, as mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications for higher dosing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of immunosuppressants and immunomodulators to treat granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with CVID is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=see_link&amp;anchor=H7222797#H7222797\">",
"     \"Pulmonary complications of primary immunodeficiencies\", section on 'Common variable immunodeficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most acute or chronic diarrheal illnesses in CVID patients are non-infectious in etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/24\">",
"     24",
"    </a>",
"    ]. CVID patients with recurrent or chronic diarrhea should be referred to a gastrointestinal specialist.",
"   </p>",
"   <p>",
"    Prolonged diarrhea can lead to malabsorption of vitamins B12 and E and patients should be monitored for deficiency. Vitamin E deficiency has been described in a CVID patient with severe enteropathy presenting as sensory loss, ataxia, and retinitis pigmentosa [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/25\">",
"     25",
"    </a>",
"    ]. Intake and output should be monitored and supplements, including protein, vitamins, and minerals (iron, zinc), supplied as required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop significant enteropathies or Crohn's-like colitis, may require antiinflammatory (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    ) or immunosuppressive therapy, such as short courses of glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    has been used with significant clinical improvement in a few patients with severe enteropathy, although this agent may be associated with an increased risk of fungal lung infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with severe enteropathy and colitis leading to malnutrition may require supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H2283068#H2283068\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Total parenteral nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic disorders are the most common form of autoimmune disease in CVID patients. A review of 326 patients found that 11 percent had a history of immune thrombocytopenia (ITP), Coombs' positive autoimmune hemolytic anemia (AIHA), or Evans' syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/14\">",
"     14",
"    </a>",
"    ]. Most of these developed hematologic autoimmune disease before or concurrent with the diagnosis of CVID and initiation of IVIG, rather than after [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/14,27\">",
"     14,27",
"    </a>",
"    ]. It is possible that IVIG may provide some protection against these disorders or recurrences of them, although this has not been demonstrated.",
"   </p>",
"   <p>",
"    For both ITP and AIHA, glucocorticoids have traditionally been the first line treatment. If ITP occurs while on IG replacement, higher doses of IG therapy (eg, 1 to 2",
"    <span class=\"nowrap\">",
"     grams/kilogram)",
"    </span>",
"    can be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/14\">",
"     14",
"    </a>",
"    ] with or without IV solumedrol. The treatment of these conditions is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with CVID and ITP or AIHA refractory to glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been used successfully and should be considered next [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In most cases, glucocorticoids are continued until the effects of rituximab can be assessed. In a retrospective analysis of 33 adults and children with ITP, AIHA, or both, overall response rate to rituximab was 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/28\">",
"     28",
"    </a>",
"    ]. Ten patients relapsed, of whom 7 of 9 responded to repeat treatment. The incidence of serious infections was not increased in patients who were receiving adequate IG replacement. Thus, rituximab would be preferred over splenectomy. Immune globulin should be continued during rituximab therapy. Rituximab dosing for ITP and AIHA is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H957606#H957606\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other second line therapy options include one or two doses of vinca alkaloids, which have been used with moderate success in steroid-resistant ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/31\">",
"     31",
"    </a>",
"    ]. Splenectomy can be used as treatment of severe refractory ITP and AIHA in patients with CVID, however it should only be considered if all other measures, (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) have failed, as it puts patients at further risk for infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Granulomatous disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiinflammatory or immunomodulatory therapy may also be needed for the granulomatous disease associated with CVID, however, there are no standard treatment protocols and responses are variable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/23,32\">",
"     23,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective analysis of 59 patients with granulomatous infiltration of various organs, 32 patients were treated, most commonly with glucocorticoids (initial dose, 30 to 60 mg daily for a median of 18 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/32\">",
"       32",
"      </a>",
"      ]. Overall, 58 percent of those receiving glucocorticoids showed a complete or partial response. Granulomas of the lymph nodes seemed more responsive than granulomas in other organs, although none of the four patients with gastrointestinal granuloma responded. Other drugs that were helpful in some patients included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The suggestion that a small subgroup of patients with CVID may have elevated production of tumor necrosis factor (TNF)-alpha has led to use of TNF inhibitors in some patients with granulomatous conditions. Case reports have documented the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cutaneous granulomas refractory to other therapies responded to the soluble TNF-alpha receptor fusion protein,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pulmonary granulomatous disease and severe systemic granulomatous disease have reportedly responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , a chimeric monoclonal antibody to TNF-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other chronic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study reported elevated rates of sensorineural hearing loss in children with CVID, possibly secondary to repeated episodes of otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/38\">",
"     38",
"    </a>",
"    ]. Complete audiological examinations should be considered in patients who display signs of impaired hearing or perform poorly in school.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DETECTION OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CVID must be monitored for lymphoma, gastric cancer, and other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/22,39,40\">",
"     22,39,40",
"    </a>",
"    ]. Specifically, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CVID should receive all age-appropriate cancer screening procedures that are recommended for the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many patients have lymphadenopathy and splenomegaly, although the onset of constitutional symptoms, solitary nodules, expanding lymph nodes, or other masses should prompt evaluation for lymphoma. This may involve lymph node or bone marrow biopsy to assess clonality.",
"     </li>",
"     <li>",
"      Bronchoscopy with biopsy may be indicated for focal pulmonary findings that fail to resolve with treatment.",
"     </li>",
"     <li>",
"      In older studies, gastric cancer was found more commonly in CVID patients, although it has not been seen with the same higher incidence in recent studies. Routine screening for gastric cancer has not been suggested for patients with CVID. Rather, patients with gastritis or gastroesophageal reflux disease who require endoscopy should also undergo biopsy for H. pylori. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"       \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8002344\">",
"    <span class=\"h2\">",
"     Cautious use of radiation-based tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of radiation-based imaging studies in patients with CVID should be conservative and thoughtful, since they are at higher baseline risk for malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Clinicians should attempt to minimize cumulative radiation exposure by choosing computed tomography protocols that use reduced radiation dose intensity whenever possible, or magnetic resonance imaging (MRI), which may be also adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-2 treatment has undergone evaluation in patients with CVID because of data demonstrating deficiency of IL-2 production in some patients and observed T cell defects that might be explained by a deficiency in IL-2. Investigational studies of low-dose IL-2 treatment resulted in improved T cell function as well as novel antibody production in response to neoantigen vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, there were only modest improvements of clinical parameters. This therapy might be considered in the treatment of refractory infections in subjects with CVID who have demonstrated defects in T cell function.",
"   </p>",
"   <p>",
"    Allogeneic stem cell transplant (ASCT) has been performed in a small number of patients with CVID, either for the treatment of hematologic malignancies or for severe manifestations of CVID that were not responding to other interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/48\">",
"     48",
"    </a>",
"    ]. One patient had an excellent outcome, with reversal of the major immunologic abnormalities and long-term disease-free survival, although others did not fare as well. Thus, ASCT could be considered in individuals with malignancies or severe disease refractory to other options after a careful risk benefit analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of death associated with acute bacterial infection in CVID decreased dramatically with the advent of immunoglobulin treatment. Thereafter, the major causes of death have been complications of chronic lung disease and malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/40,49-52\">",
"     40,49-52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series of 473 patients reported long-term data for 411 individuals, followed over a period of 40 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/50\">",
"       50",
"      </a>",
"      ]. During this time, 19.6 percent died, with a median age at death of 44 and 42 for females and males, respectively. The leading causes of death were respiratory failure due to chronic lung disease (36 percent), lymphoid and other malignancies (29 percent), and liver disease (9 percent). Reduced survival was seen in patients with gastrointestinal disease, chronic lung disease, hepatic disease, and lymphoma, although not in those with other complications, such as autoimmune disorders, granuloma, or bronchiectasis without other lung disease. Long-term survival was excellent in patients with only infectious complications, but significantly lower in those with one or more non-infectious complications (95 versus 42 percent at 40 years, respectively). Immunologic parameters associated with higher mortality were lower levels of serum IgG, increased serum IgM, and lower percentages of circulating B cells.",
"     </li>",
"     <li>",
"      Another center reported on the 353 patients diagnosed as adults, also followed over a 40-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/52\">",
"       52",
"      </a>",
"      ]. Mortality in this group was very similar at 19.5 percent, with a median age at death of 54 and 53 from females and males, respectively. The leading cause of death was chronic lung disease (30 percent). A similar percentage of patients succumbed to lymphoma, while a higher percentage died from other types of malignancies.",
"     </li>",
"     <li>",
"      In a third series of 334 patients, mortality was highest in patients with bronchiectasis, enteropathy, polyclonal lymphocytic infiltration, and autoimmunity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30457/abstract/51\">",
"       51",
"      </a>",
"      ]. In this series, there were no associations between survival and gender or initial serum IgG, IgA, or IgM levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent research has demonstrated that the percentage of circulating class-switched memory B cells can be useful in predicting a patient's risk for the development of certain complications of CVID, such as lymphoid hyperplasia, granulomatous disease, or autoimmune disorders. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of common variable immunodeficiency (CVID) involves sufficient gammaglobulin (IG) replacement therapy and monitoring for and treatment of associated inflammatory disorders and malignancies. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     IG replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;IG replacement therapy reduces the frequency of most types of infections in patients with CVID. It may also slow the progression of chronic lung disease and offer some protection against autoimmune disorders. However, there is little evidence that IG therapy protects against the development of malignancy or granulomatous disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Impact of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with CVID receive IG replacement therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The usual initial dosing for intravenous IG (IVIG) is 300 to 400",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      given every three to four weeks, with the goal of maintaining a trough IgG level in the middle of the normal range and reducing the incidence of significant infections. Some patients require more IG than others to attain these goals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immunoglobulin replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest higher doses of IG replacement for CVID patients with chronic pulmonary disease or autoimmune hematologic disorders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications for higher dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may prefer subcutaneous IG therapy, as this can be self-administered at home and is more convenient for many. Subcutaneous administration is medically indicated for patients with reactions to IVIG, those with rapid IG loss, and those with poor intravenous access. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=see_link\">",
"       \"Subcutaneous and intramuscular immune globulin therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Approach to infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with IG replacement does not entirely eliminate infections in most patients with CVID, and antibiotic therapy is also essential.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest prophylactic antibiotics to prevent infections in CVID patients with ongoing lung disease despite Ig replacement therapy, and in those requiring chronic glucocorticoids or other immunosuppressive medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We do not routinely give prophylactic antibiotics to all CVID patients and the utility of this intervention has not been adequately studied. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H18#H18\">",
"       \"Medical management of immune deficiency\", section on 'Prophylactic antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with CVID do not usually clear common infections without antibiotics, and antibiotic therapy should be instituted early for common infections, such as bronchitis and acute sinusitis. In addition, longer courses of therapy are sometimes required to eradicate infections completely. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of specific infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with CVID who plan to travel receive the appropriate vaccinations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some patients may only mount a partial response. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Vaccinations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Approach to non-infectious disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CVID may require immunosuppressive therapies for autoimmune, inflammatory, and granulomatous disorders, although they appear to suffer from higher rates of infectious and neoplastic adverse effects. Patients requiring such therapies should be carefully monitored for the specific complications associated with the agent in question. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Therapy for non-infectious disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CVID should undergo all age-appropriate cancer screening and additionally be monitored for signs and symptoms of lymphoma. These include constitutional symptoms, solitary nodules, expanding lymph nodes, other masses, and focal pulmonary findings that fail to resolve with treatment. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Detection of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/1\">",
"      Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/2\">",
"      Ellis EF, Henney CS. Adverse reactions following administration of human gamma globulin. J Allergy 1969; 43:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/3\">",
"      Friedli HR. Methodology and safety considerations in the production of an intravenous immunoglobulin preparation. Pharmacotherapy 1987; 7:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/4\">",
"      Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/5\">",
"      de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/6\">",
"      Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999; 104:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/7\">",
"      Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/8\">",
"      Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984; 101:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/9\">",
"      Pourpak Z, Aghamohammadi A, Sedighipour L, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 2006; 39:114.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham-Rundles C. Common variable immunodeficiency. In: Immunologic disorders in infants and children, 5th ed, Stiehm ERS, Ochs HD, Winkelstein JA (Eds), Philadelphia 2004. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/11\">",
"      Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001; 135:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/12\">",
"      Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987; 1:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/13\">",
"      Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J 1988; 7:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/14\">",
"      Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/15\">",
"      Samuelson A, Borrelli S, Gustafson R, et al. Characterization of Haemophilus influenzae isolates from the respiratory tract of patients with primary antibody deficiencies: evidence for persistent colonizations. Scand J Infect Dis 1995; 27:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/16\">",
"      Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005; 116:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/17\">",
"      Vorechovsk&yacute; I, Scott D, Haeney MR, Webster DA. Chromosomal radiosensitivity in common variable immune deficiency. Mutat Res 1993; 290:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/18\">",
"      Palanduz S, Palanduz A, Yalcin I, et al. In vitro chromosomal radiosensitivity in common variable immune deficiency. Clin Immunol Immunopathol 1998; 86:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/19\">",
"      Ogi M, Yokoyama H, Tomosugi N, et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994; 24:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/20\">",
"      Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 2007; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/21\">",
"      Sewell WA. CCVID patients may not respond to influenza immunization. Clin Immunol 2005; 114:210; author reply 211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/22\">",
"      Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/23\">",
"      Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev 2006; 5:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/24\">",
"      Nathan JA, Sharples LD, Exley AR, et al. The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency. J Heart Lung Transplant 2005; 24:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/25\">",
"      Aslam A, Misbah SA, Talbot K, Chapel H. Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency. Clin Immunol 2004; 112:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/26\">",
"      Chua I, Standish R, Lear S, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol 2007; 150:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/27\">",
"      S&egrave;ve P, Bourdillon L, Sarrot-Reynauld F, et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine (Baltimore) 2008; 87:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/28\">",
"      Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011; 155:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/29\">",
"      Mah&eacute;vas M, Le Page L, Salle V, et al. Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency. Am J Hematol 2006; 81:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/30\">",
"      El-Shanawany TM, Williams PE, Jolles S. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol 2007; 60:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/31\">",
"      Sikorska A, Somkowski M, Marlanka K, et al. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. Clin Lab Haematol 2004; 26:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/32\">",
"      Boursiquot JN, G&eacute;rard L, Malphettes M, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013; 33:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/33\">",
"      Chase NM, Verbsky JW, Hintermeyer MK, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 2013; 33:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/34\">",
"      Lin JH, Liebhaber M, Roberts RL, et al. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol 2006; 117:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/35\">",
"      Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein. Br J Dermatol 2001; 144:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/36\">",
"      Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol 2005; 95:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/37\">",
"      Hatab AZ, Ballas ZK. Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. J Allergy Clin Immunol 2005; 116:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/38\">",
"      Berlucchi M, Soresina A, Redaelli De Zinis LO, et al. Sensorineural hearing loss in primary antibody deficiency disorders. J Pediatr 2008; 153:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/39\">",
"      Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/40\">",
"      Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/41\">",
"      Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol 2009; 157 Suppl 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/42\">",
"      Touw CM, van de Ven AA, de Jong PA, et al. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol 2010; 21:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/43\">",
"      Turner PJ, Mehr S, Kemp AS. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol 2011; 22:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/44\">",
"      van de Ven AA, de Jong PA, Terheggen-Lagro SW, van Montfrans JM. High-resolution computed tomography in pediatric common variable immunodeficiency: risks and benefits. Pediatr Allergy Immunol 2011; 22:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/45\">",
"      Serra G, Milito C, Mitrevski M, et al. Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity. Chest 2011; 140:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/46\">",
"      Cunningham-Rundles C, Bodian C, Ochs HD, et al. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol 2001; 100:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/47\">",
"      Rump JA, Jahreis A, Schlesier M, et al. A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID). Clin Exp Immunol 1997; 110:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/48\">",
"      Rizzi M, Neumann C, Fielding AK, et al. Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J Allergy Clin Immunol 2011; 128:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/49\">",
"      Aghamohammadi A, Pouladi N, Parvaneh N, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr 2007; 53:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/50\">",
"      Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/51\">",
"      Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30457/abstract/52\">",
"      Quinti I, Agostini C, Tabolli S, et al. Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood 2012; 120:1953.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3952 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30457=[""].join("\n");
var outline_f29_47_30457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOGLOBULIN REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impact of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - On progression of chronic lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - On other complications of CVID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overview of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intravenous route",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Indications for higher dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Subcutaneous route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prophylactic antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Patients with low CD4 counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of specific infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Gastrointestinal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      GENERAL MEASURES TO AVOID INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      VACCINATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      THERAPY FOR NON-INFECTIOUS DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Granulomatous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other chronic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DETECTION OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8002344\">",
"      Cautious use of radiation-based tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      INVESTIGATIONAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      IG replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Approach to infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Approach to non-infectious disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26537?source=related_link\">",
"      Microbiology and antibiotic management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=related_link\">",
"      Nutrition and dietary interventions in adults with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37978?source=related_link\">",
"      Pulmonary complications of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/9/31896?source=related_link\">",
"      Subcutaneous and intramuscular immune globulin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=related_link\">",
"      Treatment and prevention of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_47_30458="Approach to the child with recurrent infections";
var content_f29_47_30458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with recurrent infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30458/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30458/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30458/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30458/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/47/30458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/47/30458/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/47/30458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common reason for bringing an infant or child for a medical visit is recurrent infections. This may refer to infections that are too great in number, too severe, or too long lasting; that are associated with unusual complications; or that fail to resolve with standard therapy. The causes are multiple and can be grouped into four categories: the normal child, the child with atopic disease, the child with another chronic condition, and the child with an immunodeficiency.",
"   </p>",
"   <p>",
"    The approach to the child with recurrent infections will be reviewed here. Laboratory studies evaluating the function of the immune system and specific immunodeficiencies are discussed briefly here and in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"     \"Syndromic immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5015545\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of this diagnostic approach is to differentiate the child with a primary immunodeficiency from the normal child who had more than the average number of viral infections or the child who has an underlying disease that mimics infection, predisposes the child to certain types of infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    results in secondary immune system dysfunction. Most often these categories can be determined from the history, physical examination, and screening investigations.",
"   </p>",
"   <p>",
"    Recurrent infections are infections that are too great in number, too severe, or too long lasting. Recurrent infections are defined as two or more severe infections in one year, three or more respiratory infections (eg, sinusitis, otitis, bronchitis) in one year, or the need for antibiotics for two",
"    <span class=\"nowrap\">",
"     months/year.",
"    </span>",
"    <span class=\"nowrap\">",
"     Severe/serious",
"    </span>",
"    infections include those with persistent fever or confinement to bed for a week or more, failure to respond to oral antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the need for intravenous antibiotics or hospitalization, infections with an unusual pathogen, unusual complications (eg mastoiditis, pleural effusion, abscesses), or persistent laboratory abnormalities (eg, leukocytosis, elevated",
"    <span class=\"nowrap\">",
"     ESR/CRP,",
"    </span>",
"    persistent imaging abnormalities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5015731\">",
"    <span class=\"h2\">",
"     Clinical features suggestive of a primary immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following features should lead to suspicion of an immunodeficiency and consideration of referral to an immunology specialist for evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of immunodeficiency or unexplained early death (eg, before age 30)",
"     </li>",
"     <li>",
"      Failure to gain weight or grow normally (failure to thrive)",
"     </li>",
"     <li>",
"      Need for intravenous antibiotics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hospitalization to clear infections",
"     </li>",
"     <li>",
"      Six or more new infections within one year",
"     </li>",
"     <li>",
"      Two or more serious sinus infections or pneumonias within one year",
"     </li>",
"     <li>",
"      Four or more new ear infections within one year",
"     </li>",
"     <li>",
"      Two or more episodes of sepsis or meningitis in a life time",
"     </li>",
"     <li>",
"      Two or more months of antibiotics with little effect",
"     </li>",
"     <li>",
"      Recurrent or resistant candidiasis",
"     </li>",
"     <li>",
"      Recurrent tissue or organ abscesses",
"     </li>",
"     <li>",
"      Infection with an opportunistic organism",
"     </li>",
"     <li>",
"      Complications from a live vaccine (eg, rotavirus, varicella, and Bacillus Calmette-Guerin vaccines)",
"     </li>",
"     <li>",
"      Chronic diarrhea",
"     </li>",
"     <li>",
"      Nonhealing wounds",
"     </li>",
"     <li>",
"      Extensive skin lesions",
"     </li>",
"     <li>",
"      Persistent lymphopenia (a count of &lt;1500",
"      <span class=\"nowrap\">",
"       cells/uL",
"      </span>",
"      in patients over five years and &lt;2500",
"      <span class=\"nowrap\">",
"       cells/uL",
"      </span>",
"      in younger children)",
"     </li>",
"     <li>",
"      Unexplained autoimmunity or fevers",
"     </li>",
"     <li>",
"      Granulomas",
"     </li>",
"     <li>",
"      Hemophagocytic lymphohistiocytosis (HLH)",
"     </li>",
"     <li>",
"      Lymphoma in infancy",
"     </li>",
"     <li>",
"      Features typical of syndromic primary immunodeficiencies (eg, cartilage-hair hypoplasia, Chediak-Higashi syndrome, ataxia-telangiectasia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"       \"Syndromic immunodeficiencies\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Family history of immunodeficiency was the most predictive factor of any primary immunodeficiency (PID) in a retrospective survey of 563 children who presented to two pediatric immunodeficiency centers for evaluation of possible PID [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, the use of intravenous antibiotics for sepsis and failure to thrive were strong identifiers of neutrophil PID and T cell PID, respectively.",
"   </p>",
"   <p>",
"    In infants, additional features suggestive of a primary immunodeficiency include hypocalcemia with or without seizures, congenital heart defects (mainly conotruncal anomalies), absence of thymic shadow on chest radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67690 \" href=\"UTD.htm?28/56/29571\">",
"     image 1",
"    </a>",
"    ), and delayed umbilical cord detachment (&gt;30 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe combined immunodeficiency (SCID) is considered a pediatric emergency, and special precautions should be taken if this diagnosis is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H11#H11\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H41\">",
"     'Management of the child with recurrent infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAJOR CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children who present with recurrent infections, especially localized to one organ system, have increased exposure, allergy, or chronic disease, including anatomic problems, rather than a defect in immune response. The percentages seen in each group listed below are based upon the author's clinical experience and may vary regionally depending upon the population and referral patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The \"normal\" child",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 50 percent of children with recurrent infections referred for evaluation have no known significant cause for these infections.",
"   </p>",
"   <p>",
"    Infants and children vary considerably as to the number of infections experienced. The average child has four to eight respiratory infections per year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Some infants and young children who are kept away from strangers have only one or two infections per year. Others may have 10 to 12 infections per year, particularly if they have older siblings or if they attend daycare or preschool. Exposure to passive smoking also increases the risk of upper respiratory infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean duration of viral respiratory symptoms is eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the normal range can extend beyond two weeks, which means that the \"normal\" child with over 10 viral respiratory infections can have symptoms for nearly one-half of a year.",
"   </p>",
"   <p>",
"    With regard to the number and types of infections seen, most of the respiratory infections are viral. These children generally do not have more than one episode of pneumonia or more than two episodes of uncomplicated otitis media in the first three years of life.",
"   </p>",
"   <p>",
"    These children have normal growth and development, respond quickly to appropriate treatment, recover completely, and appear healthy between infections. The physical examination and laboratory tests are normal. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Physical examination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Laboratory evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An unusual cause of recurrent infection in a normal child is Munchausen syndrome by proxy, a form of child abuse. These children have a history of repeated illnesses, based upon the testimony of the caretaker (usually the mother), that often require repeated diagnostic procedures, treatment with multiple medicines, and frequent school absenteeism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hospitalizations. Common infectious complaints include fever, cough, recurrent skin infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea. These illnesses are not validated by repeated medical examinations, and the child often gets better in the hospital or in the absence of the caregiver.",
"   </p>",
"   <p>",
"    Occasionally the caregiver induces an infection by putting contaminated material (saliva, urine, feces) in an intravenous line, on the skin, or in the ears. Bacterial cultures are mixed and mimic the profile present in the contaminating material.",
"   </p>",
"   <p>",
"    The caregiver often resists stopping medications (such as antibiotics or immunoglobulin infusions) or discharging the child from the hospital. In addition, the caregiver often has a history of abnormal behavior and may be seeking attention. A full description of the syndrome is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The child with atopic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 30 percent of children with recurrent infections have atopic disease. Chronic allergic rhinitis may be mistaken for chronic or recurrent upper respiratory infections. Children with atopic disease often develop coughing and wheezing following viral respiratory infections. These symptoms are frequently misdiagnosed as pneumonia or bronchitis rather than reactive airways",
"    <span class=\"nowrap\">",
"     disease/asthma.",
"    </span>",
"    These episodes respond poorly to antibiotics, but well to",
"    <span class=\"nowrap\">",
"     allergy/asthma",
"    </span>",
"    medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with atopic disease are more likely to develop recurrent and persistent upper respiratory infections, such as sinusitis, rhinitis, and otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/13\">",
"     13",
"    </a>",
"    ]. This increased susceptibility to infection may be due to enhanced adherence of pathogens to inflamed respiratory epithelium, increased mucosal permeability, or an altered immune response to certain viral and bacterial pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/14\">",
"     14",
"    </a>",
"    ]. The specific type of infection tends to recur in a given child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Predisposing factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Growth and development are usually normal. Children with atopy often have characteristic physical findings, such as \"allergic shiners\" or a transverse nasal crease. A total IgE is sometimes included in the laboratory screening for immunodeficiency. A normal total IgE tends to exclude IgE-mediated allergy, although it may be falsely negative in an infant. An elevated IgE (eg, &gt;100",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    is suggestive of allergy, but an elevated IgE alone is not diagnostic for atopic disease. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Physical examination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'General screening tests'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that primary immunodeficiencies and allergic disease can coexist. In a retrospective series of children evaluated for primary immunodeficiency, 31 percent",
"    <span class=\"nowrap\">",
"     (9/29)",
"    </span>",
"    who had evidence of antigen-specific IgE by skin prick or blood testing were diagnosed with an immunodeficiency compared with 9 percent",
"    <span class=\"nowrap\">",
"     (6/68)",
"    </span>",
"    of those who were negative on specific IgE testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/15\">",
"     15",
"    </a>",
"    ]. Immunodeficiencies with associated atopy include selective IgA deficiency, common variable immunodeficiency, chronic granulomatous disease, and DiGeorge syndrome. Immunodeficiencies in which elevated levels of IgE are seen include hyper IgE syndrome, Wiskott-Aldrich syndrome, Omenn syndrome, and IPEX syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The child with chronic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten percent of children with recurrent infections have an underlying chronic disease other than atopy or immunodeficiency. The child with a nonimmune chronic illness often presents with poor",
"    <span class=\"nowrap\">",
"     growth/failure",
"    </span>",
"    to thrive, a sickly appearance, and physical findings characteristic of the specific chronic disease. Diseases in this category include cystic fibrosis, gastroesophageal reflux, congenital heart disease, and chronic aspiration. Patients may also have an underlying anatomic defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H7#H7\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Overview of clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"     \"Gastroesophageal reflux in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=see_link\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link\">",
"     \"Aspiration due to swallowing dysfunction in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in this group are more susceptible to infection for various reasons, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Barrier failure - Skin or sinus",
"      <span class=\"nowrap\">",
"       tracts/fistulae,",
"      </span>",
"      or structural defects involving the cribriform plate or other parts of the skull",
"     </li>",
"     <li>",
"      Inadequate clearance of secretions - Hypotonia or a central nervous system (CNS) abnormality leading to aspiration, abnormal cilia structure or function, abnormal mucus production",
"     </li>",
"     <li>",
"      Obstruction - Eustachian tube dysfunction, tonsillar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adenoidal hypertrophy, ureteropelvic junction obstruction, chronic obstructive pulmonary disease",
"     </li>",
"     <li>",
"      Cardiovascular problems - Heart disease with increased pulmonary blood flow, structurally abnormal cardiac valve",
"     </li>",
"     <li>",
"      Foreign body - Central venous line, ventriculoperitoneal shunt, artificial cardiac valve, indwelling catheter, or noniatrogenic foreign body typically found in the nose, ear, or airway",
"     </li>",
"     <li>",
"      Resistant organisms - Penicillin resistant pneumococcus, pseudomonas,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      resistant enterococcus, multidrug resistant Mycobacterium tuberculosis (recurrent skin infections caused by community associated methicillin-resistant Staphylococcus aureus [MRSA] are common both in children with chronic disease and in normal children despite appropriate antibiotic therapy)",
"     </li>",
"     <li>",
"      Continuous reinfection - Contaminated water supply, chronically infected pet",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The child with an immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten percent of children with recurrent infections have an immunodeficiency, with a defect in one or more components of the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2\">",
"     2",
"    </a>",
"    ]. Components of the adaptive immune system include B cells (humoral or antibody system) and T cells (cellular system). The innate immune system is made up of the phagocytic cell system and the complement system. Other components of the innate immune system include Toll-like receptor transduction factors, mannose binding protein, and respiratory tract cilia.",
"   </p>",
"   <p>",
"    Immunodeficiency may be secondary or primary. Secondary immunodeficiencies usually occur well after infancy while most primary immunodeficiencies are inherited and present during the first years of life. Both primary and secondary immunodeficiency can lead to an increased susceptibility to malignancy and autoimmune disease. Primary immunodeficiencies most often affect B cell function, while secondary immunodeficiencies more often affect T cells (the cellular system).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5016183\">",
"    <span class=\"h3\">",
"     Primary immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of primary immunodeficiencies is 1 in 10,000. The prevalence of diagnosed primary immunodeficiency in the United States in 2005 was 1 in 2000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/17\">",
"     17",
"    </a>",
"    ]. More than 150 disorders have been characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2,3,18\">",
"     2,3,18",
"    </a>",
"    ]. The type and pattern of recurring infections depend on which components of the immune system are affected (",
"    <a class=\"graphic graphic_table graphicRef74045 \" href=\"UTD.htm?3/4/3149\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Infection severity also varies, ranging from mild respiratory infections to overwhelming systemic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5015731\">",
"     'Clinical features suggestive of a primary immunodeficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Almost three-fourths of the primary immunodeficiencies are caused by an antibody (B cell) deficiency or a combined antibody plus cellular (T cell) abnormality (",
"    <a class=\"graphic graphic_figure graphicRef80845 \" href=\"UTD.htm?8/31/8703\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/3\">",
"     3",
"    </a>",
"    ]. Isolated T cell defects, as well as phagocytic cell, complement, and other innate immune defects, are much less common. Thus, B cell (antibody) or combined B and T cell diseases should be considered initially, unless clinical features suggest otherwise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link&amp;anchor=H20#H20\">",
"     \"Toll-like receptors: Roles in disease and therapy\", section on 'Primary immunodeficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Secondary immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying disease states, medications, injury, previous surgical procedures, and prematurity can lead to immune system dysfunction. Secondary immunodeficiencies are more common than primary immunodeficiencies. Over 50 disorders leading to secondary immunodeficiency have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/3\">",
"     3",
"    </a>",
"    ]. Common examples include",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    diabetes mellitus, malignancy, and immunosuppressive drugs. Secondary immune deficiencies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"     \"Secondary immune deficiency due to miscellaneous causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Birth history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy history should be explored for maternal illness (eg, HIV, CMV), risky behaviors and exposure to toxins, prescription medications, illicit drugs, tobacco, and alcohol. Birth history should include length of gestation, birth weight, and neonatal problems, such as jaundice, respiratory distress, or need for intensive care. Transfusions in the neonatal period should be recorded.",
"   </p>",
"   <p>",
"    Feeding history, including food intolerance and duration of breast feeding, should be reviewed. Delayed detachment of the umbilical cord should be noted since persistent attachment beyond 30 days is suggestive of a leukocyte adhesion defect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=see_link\">",
"     \"Leukocyte adhesion deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Growth and development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight, height, and head circumference should be plotted and followed over time. Children with chronic disease or immunodeficiency often have poor weight gain or even weight loss. This is particularly true in the presence of oral ulcers, candidiasis, or chronic diarrhea. Children with chronic lung, heart, or gastrointestinal disease are often small because of anorexia, high energy expenditure, or malabsorption caused by infection or bacterial overgrowth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38233?source=see_link&amp;anchor=H5#H5\">",
"     \"Poor weight gain in children older than two years of age\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functional assessment of a child's development should be made in the following five areas: motor (gross and fine), language, cognitive, social, and emotional. Chronic disease and certain primary immunodeficiencies, most notably the syndromic immunodeficiencies, such as ataxia-telangiectasia and DiGeorge syndrome, can lead to delay in attaining developmental milestones. Progressive neurologic dysfunction is seen in young adults with Chediak-Higashi syndrome. Delayed speech can occur with recurrent and chronic otitis media. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"     \"Syndromic immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H307347#H307347\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'Monitoring milestones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunization history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization history should be reviewed. Details of interest include any adverse effects from a vaccine, particularly live virus vaccines (eg, CNS complications from oral polio vaccination that is still used in some regions with a higher incidence of polio, or diarrhea following",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/21\">",
"     21",
"    </a>",
"    ]) as well as vaccine failure (eg, chicken pox in a varicella vaccinated child).",
"   </p>",
"   <p>",
"    Live virus vaccines given in early infancy, including rotavirus or oral polio vaccine, are of special threat to patients with congenital immunodeficiencies (eg, agammaglobulinemia or combined immunodeficiency). Patients with T cell deficiencies or who are on immunosuppressive drugs including glucocorticoids may develop progressive infections following live virus vaccines. A person who develops infections despite immunization may be immunodeficient and should be evaluated, including measuring the antibody response to the vaccine.",
"   </p>",
"   <p>",
"    The immunization record is also valuable when examination of vaccine titers is planned to evaluate antibody function. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Antibody titers'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Vaccine challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current and past medications (including over-the-counter medicines and supplements) should be recorded, including duration, effectiveness, and adverse reactions. Use of any immunosuppressive medications, such as glucocorticoids, should be noted. If immunoglobulin has been given, the route, brand, dose, frequency, use of premedication, and adverse effects should be noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of childhood diseases, such as chickenpox, roseola, and febrile illnesses, should be noted. An inquiry about past hospitalizations, injuries or accidents, surgeries, or prolonged school absences may provide clues to the present illness. System review should include other immune problems, such as allergies, anaphylaxis, arthritis, or autoimmunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of family members with similar diseases, recurrent infections, unexplained death, or autoimmune disease suggests the possibility of a genetic illness. Inheritance patterns are variable. Many immunodeficiencies have X-linked transmission (eg, some forms of agammaglobulinemia and chronic granulomatous disease). An autosomal recessive pattern is seen in conditions such as some complement defects and ataxia-telangiectasia. An inconstant familial tendency may also be seen (eg, common variable immunodeficiency, selective IgA deficiency, hyper IgE syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inquiring about consanguinity is important when considering autosomal recessive immunodeficiencies. Certain immunodeficiencies are more common in particular ethnic populations (eg, severe combined immunodeficiency [SCID] in Navajos and ataxia-telangiectasia in Amish).",
"   </p>",
"   <p>",
"    Inquiry should also be made about infections in family members, including such illnesses as tuberculosis, hepatitis B, herpes simplex, and HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Social history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The home, parents' work environment, and daycare or school should be explored for exposures, such as allergens, tobacco smoke, contaminated water supply, farm animals, solvents, and toxins, as well as location near industrial plants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Prior residences and travel history may be important in exposure to infectious agents or allergens. Daycare and school attendance increases the risk of exposure to respiratory pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Infection history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection history should include the age of onset, duration, frequency, sites, organisms, treatment, and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Age of onset",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Birth to six months",
"      </strong>",
"      &ndash; Infections presenting shortly after birth may be secondary to prolonged rupture of membranes, congenital infection, infection exposure during the birth process, or aspiration. Premature infants, especially those needing respirators or intravenous catheters, are at high risk for infection.",
"      <br/>",
"      <br/>",
"      Several primary immunodeficiencies are associated with early onset of severe infections, notably congenital neutropenias, leukocyte adhesion defects, severe combined immunodeficiencies, and complete DiGeorge syndrome. Defects in toll-like receptor 3 (TLR3) transduction are associated with herpes simplex encephalitis of the newborn [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Six months to two years",
"      </strong>",
"      &ndash; Infants and children presenting with infection from six months to two years of age may fall into any of the four categories listed above (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Major causes'",
"      </a>",
"      above). Normal infants exposed to other children or to tobacco smoke are more prone to recurrent respiratory infections. Wheezing,",
"      <span class=\"nowrap\">",
"       eczema/atopic",
"      </span>",
"      dermatitis, and food intolerance suggest allergy. Persistent diarrhea, chronic cough, or failure to thrive suggests cystic fibrosis or a primary immunodeficiency. Congenital antibody deficiencies and many combined immunodeficiencies (eg, ZAP-70 deficiency, CD25 deficiency) usually present at 7 to 12 months as maternal IgG disappears. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"       \"Agammaglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"       \"Combined immunodeficiencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Two to six years",
"      </strong>",
"      &ndash; Children developing infection in the two to six year age range may also fit into any of the four categories outlined above. Secondary immunodeficiencies resulting from malignancy, nephrotic syndrome, or gastrointestinal problems often begin at this age. Gastrointestinal disorders can cause loss of protein or specific vitamin or mineral deficiencies due to malabsorption. Daycare or school entry often results in frequent respiratory and gastrointestinal infections. Less serious antibody deficiencies (eg, IgA deficiency and selective antibody deficiency) and combined immunodeficiencies also first present at this age. As examples, persistent candidiasis suggests chronic mucocutaneous candidiasis (CMCC), ataxia with infections suggests ataxia-telangiectasia, and growth retardation with infections suggests cartilage-hair hypoplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"       \"Syndromic immunodeficiencies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"       \"Combined immunodeficiencies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link\">",
"       \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       6 to 18 years",
"      </strong>",
"      &ndash; It is unusual for recurrent infections to first present beyond six years of age. HIV infection and other sexually transmitted diseases should be considered in adolescents. Two or more episodes of bacterial meningitis or sepsis suggest a complement or other innate immune defect [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2,3,26,28\">",
"       2,3,26,28",
"      </a>",
"      ]. Candidiasis suggests CMCC. Early onset common variable immunodeficiency can present at this time. Infections associated with vasculitic lesions, arthritis, and recurrent fever suggests autoimmunity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link\">",
"       \"Natural history and classification of pediatric HIV infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link\">",
"       \"Chronic mucocutaneous candidiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link\">",
"       \"Common variable immunodeficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sites of infection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Upper respiratory tract",
"      </strong>",
"      &ndash; The upper respiratory tract (nose, throat, ears, sinuses) is the most common site of infection. Most upper respiratory infections are viral.",
"      <br/>",
"      <br/>",
"      Chronic purulent nasal discharge and cough secondary to postnasal drainage suggest chronic sinusitis. Refractory asthma is sometimes associated with chronic sinusitis. Gastroesophageal reflux can also cause chronic cough and recurrent otitis media and sinusitis. Persistently opacified sinuses, particularly cases refractory to antibiotics, may be due to an antibody deficiency or cystic fibrosis in a small subset of patients. Unilateral purulent nasal discharge suggests a foreign body.",
"      <br/>",
"      <br/>",
"      Allergic disease is associated with chronic or seasonal clear nasal discharge, congestion, itchy eyes, nocturnal cough, and a poor response to antibiotics. Allergic rhinitis can be misdiagnosed as recurrent upper respiratory infections.",
"      <br/>",
"      <br/>",
"      Nystatin-resistant or recurrent candidiasis (after three months of age), stomatitis, gingivitis, and oral ulcerations occur in T cell and phagocytic cell disorders. Other oral manifestations of immunodeficiencies are reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/29\">",
"       29",
"      </a>",
"      ]. Recurrent aphthous ulcers suggest autoimmune disease or a periodic fever syndrome. Recurrent pharyngitis or tonsillitis is not typically associated with immunodeficiency.",
"     </li>",
"     <li>",
"      <strong>",
"       Lower respiratory tract",
"      </strong>",
"      &ndash; Recurrent pneumonia is rare in normal children or children with allergic disease, and suggests chronic cardiopulmonary disease or immunodeficiency. However, reactive airways",
"      <span class=\"nowrap\">",
"       disease/asthma",
"      </span>",
"      is often misdiagnosed as pneumonia or bronchitis in young children. Recurrent pneumonia limited to a particular anatomic region (eg, right middle lobe) is typically caused by a local anatomic abnormality (eg, foreign body, bronchial compression by mediastinal adenopathy or vascular anomaly, bronchial sequestration or cyst). By contrast, patients with sequential lower respiratory tract infections involving different regions of the lung often have an underlying systemic disorder (eg, cystic fibrosis, immotile cilia syndrome, recurrent aspiration).",
"     </li>",
"     <li>",
"      <strong>",
"       Blood and brain",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Bacterial meningitis and sepsis suggest an antibody deficiency or complement defect. Chronic enteroviral encephalomyelitis occurs in patients with profound antibody deficiency, and commonly follows oral polio vaccine.",
"      <br/>",
"      <br/>",
"      Recurrent meningitis or meningitis with an unusual organism may occur with structural defects of the cribriform plate, inner ear (Mondini defect), or sinuses; the latter is sometimes a complication of sinus surgery. A cerebrospinal fluid leak through the nose, ear, or sinuses may occur with structural defect.",
"      <br/>",
"      <br/>",
"      Brain abscesses usually result from parameningeal foci of infection, such as sinusitis or mastoiditis. Remote infections that seed the systemic arterial supply, such as lung abscesses and infective endocarditis, can also result in brain abscesses.",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &ndash; Abscesses of the skin, lymph nodes, or internal organs suggest a phagocytic or antibody deficiency. Recurrent abscesses at the same site may indicate an underlying anatomic defect, such as a congenital branchial cleft cyst, pilonidal cyst, hidradenitis suppurativa, or a retained foreign body. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Recurrent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic gastrointestinal infections occur in patients with IgA deficiency or common variable immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Recurrent urinary tract infections are uncommon in immunodeficiency and usually reflect a structural abnormality, such as obstruction, reflux, or bladder dysmotility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of the same organism repeatedly from a single site suggests a structural defect, while isolation of an organism from a normally sterile site suggests an underlying defect in immunity.",
"   </p>",
"   <p>",
"    Certain immunodeficiencies commonly present with infections caused by \"signature\" organisms. Children who present with such infections should undergo laboratory evaluation for immune deficiency. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Laboratory evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent sinopulmonary infections with encapsulated organisms (eg, pneumococcus, Haemophilus influenzae type b) suggest B cell abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent pneumococcal disease suggests a primary immunodeficiency, such as agammaglobulinemia or complement defect. Secondary immunodeficiency, due to sickle cell disease, asplenia,",
"      <span class=\"nowrap\">",
"       HIV/AIDS,",
"      </span>",
"      or nephrotic syndrome, also results in recurrent pneumococcal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumocystis jiroveci (carinii) pneumonia is a hallmark of severe combined immune deficiency (SCID) and other primary or secondary T cell immunodeficiencies, such as T cell defects associated with HIV or immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840561#H18840561\">",
"       \"Natural history and classification of pediatric HIV infection\", section on 'Other'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudomonas sepsis may occur in phagocytic disorders or in profound antibody or T cell immunodeficiency. Pseudomonas infection also occurs in patients with cystic fibrosis, burns or soft tissue injury, or neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H7#H7\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Overview of clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteroviral meningoencephalitis can be the presenting infection in children with X-linked agammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. It is rare in children receiving regular doses of intravenous immunoglobulin (IVIG). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"       \"Agammaglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aspergillus, Staphylococcus aureus, coagulase negative staphylococci, Serratia marcescens, and Chromobacterium violaceum are common organisms found in abscesses or soft tissue infections in patients with chronic granulomatous disease (CGD) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"       \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent staphylococcal skin infections, abscesses, lung cysts, or pneumonia are characteristic of hyperimmunoglobulin E syndrome (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"       \"Hyperimmunoglobulin E syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged and severe candidiasis involving the buccal mucosa, tongue, and palate may be the earliest sign of abnormal T cell immunity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"       \"Combined immunodeficiencies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link\">",
"       \"Chronic mucocutaneous candidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Invasive infection with Neisseria species (N. meningitidis, N. gonorrhoeae) occurs in patients with deficiencies of the late components of complement (C5 to C9) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/38-41\">",
"       38-41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection with vaccine strains following live vaccines, including oral rotavirus, oral polio, measles, varicella, or BCG, suggest primary immune deficiency. Vaccine failure (eg, recurrent chickenpox or shingles in the vaccinated child) also suggests immunodeficiency. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Immunization history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep or systemic infections with nontuberculous mycobacteria suggest an interferon gamma receptor or interleukin receptor deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=see_link\">",
"       \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in children with recurrent infections provides information as to their general health and may suggest the presence of allergy, chronic disease, or immunodeficiency.",
"   </p>",
"   <p>",
"    The child's overall appearance, demeanor, and activity are the first clues to the general state of health. Vital signs (including oxygen saturation if cardiac or pulmonary disease is suspected) should be recorded. Unusual dysmorphic appearance may signify a genetic syndrome.",
"   </p>",
"   <p>",
"    Growth and development is documented by growth charts and maturational milestones. Weight loss or failure to thrive is suggested by muscle wasting or atrophy of the buttock fat deposits. Profound growth failure (eg, dwarfism) is noted in some syndromic immunodeficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"     \"Syndromic immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of acute or chronic otitis media should be determined, since upper respiratory infections are the most common recurrent infection. Hearing should be evaluated in children with recurrent otitis. Draining ears and perforated tympanic membranes suggest immunodeficiency.",
"   </p>",
"   <p>",
"    Pallor without anemia, dark circles under the eyes, conjunctivitis, a transverse nasal crease, congested turbinates, and clear nasal discharge suggest allergy. Purulent nasal discharge, postnasal drip, and diminished gag reflex are consistent with chronic sinusitis. Pharyngeal cobblestoning may be seen with either allergic rhinitis or chronic sinusitis. Mouth ulcers, gingivitis, mucosal candidiasis, and poor dentition suggest immunodeficiency. Diminished or absent tonsils and cervical nodes in the presence of recurrent respiratory infections suggest an antibody deficiency. Nasal polyps suggest cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H9#H9\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Sinus disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All older patients should be asked to cough: a productive or wheezy cough suggests bronchitis, pneumonia, or asthma. Chest asymmetry, an increased posterior-anterior chest diameter, and pectus excavatum are associated with asthma and chronic lung disease. Crackles, wheezes, and abnormal breath sounds should be noted. Digital clubbing suggests long-standing lung or heart disease, inflammatory bowel disease, or chronic infection.",
"   </p>",
"   <p>",
"    Atopic dermatitis (eczema), excoriations, and dermographism suggest allergic disease. However, several immunodeficiency syndromes are associated with eczema, including Wiskott-Aldrich, hyper IgE, IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked), Omenn syndrome, and severe combined immunodeficiency (SCID). Cutaneous granulomas, impetigo, or nonhealing sores suggest antibody or phagocytic immunodeficiency. Facial rashes, vitiligo, alopecia, and vasculitic lesions suggest autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immune deficiency disorders can be characterized by an over abundance (",
"    <a class=\"graphic graphic_picture graphicRef71496 \" href=\"UTD.htm?41/31/42495\">",
"     picture 1",
"    </a>",
"    ) or paucity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62709 \" href=\"UTD.htm?15/36/15951\">",
"     image 2",
"    </a>",
"    ) of lymphoid tissue (eg, tonsils, lymph nodes, spleen) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/43\">",
"     43",
"    </a>",
"    ]. The absence of lymph tissue suggests X-linked agammaglobulinemia or severe combined immunodeficiency (SCID). However, adenopathy and hepatosplenomegaly can be seen in other B cell disorders (eg, common variable immunodeficiency [CVID], IgA deficiency) and HIV infection. Suppurative adenitis is common in chronic granulomatous disease (CGD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical patterns suggestive of immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constellations of certain findings are characteristic of specific immunodeficiency syndromes. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ataxia, telangiectasia, and developmental delay in ataxia-telangiectasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Petechiae, easy bleeding, eczema, and chronic draining ears in Wiskott-Aldrich syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coarse features, chronic infected eczema, and deep-seated abscesses in hyper IgE syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"       \"Hyperimmunoglobulin E syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Short stature with chondrodystrophy and fine hair in cartilage-hair hypoplasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7992?source=see_link\">",
"       \"Cartilage-hair hypoplasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital heart disease, developmental delay, and dysmorphic facies with low-set ears, hypertelorism, downturning eyes, and micrognathia in DiGeorge syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"       \"DiGeorge syndrome: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=see_link\">",
"       \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Early onset of seborrheic dermatitis and alopecia in some forms of SCID (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oral ulcers, gingivitis, and impetigo in chronic granulomatous disease (CGD), or leukocyte adhesion defects (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"       \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link\">",
"       \"Chronic granulomatous disease: Treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=see_link\">",
"       \"Leukocyte adhesion deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oculocutaneous albinism in Chediak-Higashi disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link\">",
"       \"Chediak-Higashi syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abnormal dentition, decreased sweating, and sparse hair associated with frequent infection suggest ectodermal dysplasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H21#H21\">",
"       \"Combined immunodeficiencies\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dermatomyositis-like rash in X-linked agammaglobulinemia (XLA) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"       \"Agammaglobulinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lupus-like rash in early complement component defects (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extensive warts or molluscum contagiosum in T cell disorders, innate immune defects, or the Warts Hypogammaglobulinemia Infections Myelokathexis (WHIM) syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link\">",
"       \"Molluscum contagiosum\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"       \"Congenital neutropenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H28#H28\">",
"       \"Combined immunodeficiencies\", section on 'Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with genetic syndromes have recurrent infection. Syndromic immunodeficiency is the term given to a variety of conditions in which the immune system is only one of several organ systems involved. These disorders are covered elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=see_link\">",
"     \"Syndromic immunodeficiencies\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation of children with recurrent infection depends upon history and physical examination findings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2\">",
"     2",
"    </a>",
"    ]. Evaluation for primary immunodeficiency should focus on the component of the immune system that is most likely to be involved based upon the initial assessment. Laboratory studies for disorders that cause secondary immune deficiency (eg, sickle cell disease, diabetes mellitus) are discussed separately (see appropriate topic reviews). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Initial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening evaluation should include both quantitative and qualitative tests. These tests are readily available, are recommended for all children with recurrent infections, and can be performed by the primary care clinician. Abnormalities of the following initial tests may suggest allergy, immunodeficiency, or a chronic illness and serve as a guide for subsequent investigations. Abnormal studies should prompt referral to the appropriate specialist, usually an immunologist. Further laboratory evaluation is probably futile if these tests are all normal. The patient's family can be reassured that infection or other serious disorder has been excluded, though further monitoring may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     General screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;General screening tests should include the following to exclude systemic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Electrolytes, glucose, BUN, creatinine, and albumin",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Special attention should be paid to the total absolute lymphocyte count: lymphopenia is defined as a count of &lt;1500",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    in patients over five years and &lt;2500",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    in younger children. The presence of anemia, thrombocytopenia, or an abnormal differential count warrants further investigation. Eosinophilia suggests allergy. Thrombocytosis suggests chronic inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3920595\">",
"    <span class=\"h3\">",
"     Immunoglobulin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin levels, including IgG, IgM, IgA, and IgE, are included in the initial tests. Levels must be compared with age-matched controls, particularly in the first two years of life.",
"   </p>",
"   <p>",
"    Antibody deficiency is suggested by an IgG less than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and a total Ig (IgG plus IgM plus IgA) less than 400",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    or the complete absence of IgM or IgA (after infancy).",
"   </p>",
"   <p>",
"    An elevated IgE (&gt;100",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    suggests allergy, eczema, or chronic skin infections, or may occur in Omenn syndrome, phagocytic disorders, or hyper IgE syndrome (levels are generally &gt;2000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    for this syndrome). Low or absent IgE levels suggest absence of IgE-mediated allergic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Infection evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for infection may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sedimentation rate (ESR) or C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Appropriate cultures",
"     </li>",
"     <li>",
"      Radiologic imaging of the site(s) of suspected infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An elevated ESR or CRP suggests systemic or regional infection or an autoimmune process.",
"   </p>",
"   <p>",
"    A nasal culture should be considered in the child with recurrent skin infection to determine if the child is a carrier of group A streptococcus or Staphylococcus aureus. If positive, family members may be cultured, particularly if they have chronic skin lesions.",
"   </p>",
"   <p>",
"    A chest x-ray is indicated if the child has a chronic cough or other features suggesting lung problems. Thymic size should be noted in chest radiographs of newborns with recurrent infections (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67690 \" href=\"UTD.htm?28/56/29571\">",
"     image 1",
"    </a>",
"    ). Sinus and lateral neck films or sinus computed tomography (CT) scan with a lateral pharyngeal view for adenoidal size is indicated for the patient with suspected sinusitis or obstructive breathing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62709 \" href=\"UTD.htm?15/36/15951\">",
"     image 2",
"    </a>",
"    ). Complete absence of adenoidal tissue suggests immunodeficiency. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'The child with atopic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3920576\">",
"    <span class=\"h2\">",
"     Intermediate tests for immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tests are indicated when the screening tests are abnormal or the clinical picture is highly suggestive for an immunodeficiency. Usually these are done by the specialist, but they can also be started by the generalist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Antibody titers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of the antibody system is best assessed by checking antibody titers to previously administered vaccines. Response to protein antigens can be assessed by measurement of titers to tetanus, diphtheria, and Hemophilus influenzae type b (anti-PRP IgG). Response to polysaccharide antigens can be determined by measurement of titers to pneumococcus in adults and children over 24 months of age. We recommend a 23 valent panel, available in many commercial laboratories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note whether or not the patient has received a conjugated (PCV7 or PCV13) or unconjugated (PPV23) pneumococcal vaccine. Positive titers to serotypes in the conjugated vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F in both Prevnar 7 and Prevnar 13 and 1, 3, 5, 6A, 7F, and 19A only in Prevnar 13) indicate an ability to respond to polysaccharides conjugated to protein antigens. To determine the ability to respond to pure polysaccharide antigens the response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    must be determined. The 23 serotype antibody panel includes the serotypes present in the PPV23 and the PCV13 vaccines. Children two to five should respond to at least 50 percent of the polysaccharide antigens (1.3",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    or greater) and older patients (6 to 60) should respond to at least 70 percent of the polysaccharide antigens.",
"   </p>",
"   <p>",
"    The author's approach is to assess baseline titers to pneumococcal serotypes. If titers are deficient and the child is over two years, the author gives unconjugated pneumococcal vaccine and rechecks titers in four to six weeks. If titers are still low, a conjugated vaccine is given and titers are retested again. This will determine if the patient can respond to protein and polysaccharide antigens.",
"   </p>",
"   <p>",
"    Natural antibodies, such as isoagglutinins (isoantibodies to blood group antigens; anti-A, anti-B), anti-streptolysin titers, and E. coli antibodies are of less value, particularly in the young infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Complement activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activity should be assessed in patients with recurrent sepsis or Neisserial infection. The screening test is a total hemolytic complement determination (CH50). A normal CH50 level excludes nearly all hereditary complement deficiencies. Levels of individual complement components are measured if the CH50 is significantly reduced or zero. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Complement component'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H5551391#H5551391\">",
"     \"Laboratory evaluation of the immune system\", section on 'Complement defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further testing is warranted when screening tests are abnormal or if there is a convincing history of immunodeficiency. These intermediate tests should provide some guidance as to which specific disorders must be considered and confirmed by additional studies. These tests should be undertaken in consultation with a pediatric immunologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Lymphocyte subset analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocyte subset analysis by flow cytometry, including CD3 (total T cells), CD4 (T helper), CD8 (T cytotoxic), CD19 or CD20 (B cells), and",
"    <span class=\"nowrap\">",
"     CD16/56",
"    </span>",
"    (natural killer cells), is indicated when a B or T cell defect is suspected. Comparison with age-matched controls is necessary (infants and young children normally have lymphocytosis compared with adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2,3,44\">",
"     2,3,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CD4 count is the most valuable reflection of the cellular immune system. An absolute CD4 count of &lt;500",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    in a person over five or &lt;1000",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    in younger children suggests a cellular immunodeficiency. An absolute B cell (CD19) count of &lt;100",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    suggests hereditary agammaglobulinemia. A low",
"    <span class=\"nowrap\">",
"     CD16/56",
"    </span>",
"    count (&lt;2 percent) suggests a natural killer cell deficiency. Low levels of any lymphocyte subset should be repeated and, if confirmed, followed by functional analysis of the respective immune system component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Vaccine challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine responsiveness is used to further assess the antibody system. A killed vaccine that has not been administered previously is given and titers are measured before and four to six weeks after vaccination. The unconjugated pneumococcal vaccine is typically used to assess response to polysaccharide antigens (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Antibody titers'",
"    </a>",
"    above). Other inactivated vaccines that the child has not yet received can be used to measure antibody function, such as hepatitis A, hepatitis B, meningococcal, and polio vaccines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     IgG subset determinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG subset determinations are sometimes of value, particularly in patients with a slightly low total IgG level and poor antibody response to vaccinations. A complete absence of IgG1, IgG2, or IgG3 suggests immune dysregulation, and may indicate the early onset of common variable immunodeficiency. A low level of one or more IgG subclasses does not, by itself, indicate an antibody deficiency; functional antibody studies must show a defect. These studies are not recommended by some immunologists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     HIV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV testing, either by antibody titers or PCR, should be done in any patient suspected of a T cell deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35525?source=see_link\">",
"     \"Diagnostic testing for HIV infection in infants and children younger than 18 months\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Delayed cutaneous hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed cutaneous hypersensitivity is a functional",
"    <em>",
"     in vivo",
"    </em>",
"    test of T cell function that may be performed in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Children under age two often have negative tests despite intact cellular immunity. The usual skin tests employ candida antigen, tetanus or tetanus-diphtheria antigen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tuberculin. A documented history of candida infection; a recent diphtheria, tetanus, or BCG vaccine; or previously positive tuberculin reaction are necessary to interpret a response to these antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H14668033#H14668033\">",
"     \"Laboratory evaluation of the immune system\", section on 'Cutaneous delayed-type hypersensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Lymphoproliferative assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoproliferative assays are",
"    <em>",
"     in vitro",
"    </em>",
"    assays used to further assess the cellular immune system. The ability of lymphocytes to proliferate to mitogens (phytohemagglutinin, concanavalin, pokeweed), stimulatory monoclonal antibodies (anti-CD3), or allogeneic cells (in a mixed leukocyte reaction) indicates intact lymphocyte activation to nonspecific stimuli. Diminished or absent proliferation to mitogens signals a serious derangement of T cell function such as severe combined immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H8#H8\">",
"     \"Laboratory evaluation of the immune system\", section on 'In vitro studies of T cell function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lack of a lymphoproliferative response to a specific antigen to which the patient has been exposed by infection or immunization (eg, candida, tuberculin, tetanus) indicates anergy and a probable T cell defect. Responses to specific antigens are diminished or even absent while mitogen responses remain intact in many cases of combined immune deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Phagocytic oxidative responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phagocytic oxidative responses are correlated with the ability of leukocytes to kill bacteria. This is best assessed using a fluorescent dye (dihydrorhodamine) and flow cytometry. A negative response is seen in chronic granulomatous disease. This procedure is faster and more informative than nitroblue tetrazolium dye reduction assays used previously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link&amp;anchor=H33#H33\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Dihydrorhodamine 123 (DHR) test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Leukocyte adhesion defect testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspected cases of leukocyte adhesion deficiency (LAD) can be evaluated by examination of cell surface marker expression by flow cytometry. CD11 and CD18 are absent in LAD I and CD15a is absent in LAD II. Patients with LAD III have normal integrin expression. Diagnosis requires demonstration of impaired integrin activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link&amp;anchor=H20#H20\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\", section on 'Leukocyte adhesion deficiencies (LAD)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=see_link\">",
"     \"Leukocyte adhesion deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Complement component",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement component assays are indicated if there is very low or absent CH50 activity on repeat testing. These assays are available through many commercial laboratories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H5551391#H5551391\">",
"     \"Laboratory evaluation of the immune system\", section on 'Complement defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Confirmatory diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definite diagnosis by advanced tests will direct treatment options, prognostic information, and genetic counseling. These advanced tests are discussed elsewhere and in the sections on the individual diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of these tests are available in specialized reference or research laboratories. A genetic diagnosis is available for over 100 different immunodeficiency syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE CHILD WITH RECURRENT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children undergoing evaluation for recurrent infection need special care during the evaluation process. This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections must be promptly recognized and aggressively treated. Empiric antibiotic therapy should be instituted pending culture results.",
"     </li>",
"     <li>",
"      Prophylactic antibiotics may be administered depending upon the type of disorder suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"       \"Medical management of immune deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Live-virus vaccines (eg, oral polio, oral rotavirus, varicella, MMR, smallpox, intranasal influenza) and the live BCG vaccine must not be administered to the child (",
"      <a class=\"graphic graphic_table graphicRef55584 \" href=\"UTD.htm?35/6/35949\">",
"       table 2",
"      </a>",
"      ). Family members may receive varicella, MMR, and shingles vaccines, but not oral polio or smallpox vaccines. Inactive influenza vaccine may be preferred for household contacts of some immune compromised individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"       \"Medical management of immune deficiency\", section on 'Vaccination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postexposure infectious prophylaxis may be necessary following exposure to varicella. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link&amp;anchor=H2#H2\">",
"       \"Post-exposure prophylaxis against varicella-zoster virus infection\", section on 'Assessment of risk of infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Only irradiated, leukocyte-poor, virus-free products should be used if blood transfusion is necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H11#H11\">",
"       \"Severe combined immunodeficiency (SCID): An overview\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) should not be given until there has been a thorough evaluation of the patient's immune system. IVIG and SCIG are expensive, will negate an antibody investigation for several months, and have potential adverse effects. Their use should be carefully considered only after the evaluation is complete.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The author will often treat the child with recurrent or chronic bacterial infections (eg, otitis media, sinusitis, bronchitis, pneumonia) with a six week course of antibiotic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/2/6181?source=see_link\">",
"     cefdinir",
"    </a>",
"    ), followed by prophylactic antibiotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally twice or three times a week, maximum dose 250",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    while the immune evaluation is ongoing. A three to six month trial of IVIG or SCIG may be indicated for documented severe chronic sinusitis, mastoiditis, pneumonia, or bronchitis, even if there is no evidence of immunodeficiency, in the uncommon event that this antibiotic regimen fails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helpful material is available for clinicians and parents from:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Immune Deficiency Foundation (",
"      <a class=\"external\" href=\"file://www.primaryimmune.org/\">",
"       www.primaryimmune.org",
"      </a>",
"      ). This includes Diagnostic and Clinical Care Guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?29/47/30458/abstract/46\">",
"       46",
"      </a>",
"      ] and a Patient and Family Handbook. A free physician-to-physician consulting immunologist program is also available.",
"     </li>",
"     <li>",
"      The Jeffrey Modell Foundation (",
"      <a class=\"external\" href=\"file://www.info4pi.org/\">",
"       www.info4pi.org",
"      </a>",
"      ) (accessed on January 31, 2012).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of children who present with recurrent infections, especially localized to one organ system, have increased exposure, allergy, or an anatomic problem rather than a defect in immune response. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Major causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary disorders of immune function should be considered in children who have recurrent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complicated bacterial infections (eg, sinopulmonary infection, recurrent soft tissue or organ abscesses, two or more episodes of bacterial sepsis or meningitis); persistent oral candidiasis; infection with opportunistic, unusual, or \"signature\" organisms; failure to thrive; or a family history of immunodeficiency or unexplained early deaths. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Major causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful history and physical examination can usually isolate the disorder to one of the four components of the immune system in children in whom a primary immunodeficiency is suspected. B cell and combined B and T cell abnormalities account for nearly three-fourths of the primary immunodeficiencies and should be considered initially. Isolated T cell, phagocytic, and complement defects are rare. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The screening evaluation should include both quantitative and qualitative tests. Screening tests may include a complete blood count with differential, chemistry studies, urinalysis, sedimentation rate or CRP, appropriate cultures, radiologic imaging of the infection site, immunoglobulin levels, antibody titers to vaccine antigens, and complement activity. Definitive diagnostic testing should be performed if the initial screening evaluation is abnormal. Definitive testing should be undertaken in consultation with a pediatric immunologist. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"       \"Laboratory evaluation of the immune system\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/1\">",
"      Bush A. Recurrent respiratory infections. Pediatr Clin North Am 2009; 56:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/2\">",
"      Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: general considerations. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Saunders/Elsevier, 2004. p.289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/4\">",
"      Wheeler JG. Evaluating the child with recurrent infections. Am Fam Physician 1996; 54:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/5\">",
"      Ballow M. Approach to the patient with recurrent infections. Clin Rev Allergy Immunol 2008; 34:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/6\">",
"      Slatter MA, Gennery AR. Clinical immunology review series: an approach to the patient with recurrent infections in childhood. Clin Exp Immunol 2008; 152:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/7\">",
"      Carneiro-Sampaio M, Jacob CM, Leone CR. A proposal of warning signs for primary immunodeficiencies in the first year of life. Pediatr Allergy Immunol 2011; 22:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/8\">",
"      Subbarayan A, Colarusso G, Hughes SM, et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics 2011; 127:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/9\">",
"      Monto AS. Viral respiratory infections in the community: epidemiology, agents, and interventions. Am J Med 1995; 99:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/10\">",
"      Campbell H. Acute respiratory infection: a global challenge. Arch Dis Child 1995; 73:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/11\">",
"      Gr&uuml;ber C, Keil T, Kulig M, et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol 2008; 19:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/12\">",
"      Environmental tobacco smoke: a hazard to children. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1997; 99:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/13\">",
"      Daly KA, Hoffman HJ, Kvaerner KJ, et al. Epidemiology, natural history, and risk factors: panel report from the Ninth International Research Conference on Otitis Media. Int J Pediatr Otorhinolaryngol 2010; 74:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/14\">",
"      James KM, Peebles RS Jr, Hartert TV. Response to infections in patients with asthma and atopic disease: an epiphenomenon or reflection of host susceptibility? J Allergy Clin Immunol 2012; 130:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/15\">",
"      MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol 2011; 22:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/16\">",
"      Skoda-Smith S, Barrett DJ. When earaches and sore throats become more than a pain in the neck. Contemp Pediatr 2000; 17:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/17\">",
"      Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007; 27:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/18\">",
"      International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009; 124:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/19\">",
"      Woroniecka M, Ballow M. Office evaluation of children with recurrent infection. Pediatr Clin North Am 2000; 47:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/20\">",
"      Etzioni A. Adhesion molecules--their role in health and disease. Pediatr Res 1996; 39:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/21\">",
"      Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/22\">",
"      Owen MJ, Baldwin CD, Swank PR, et al. Relation of infant feeding practices, cigarette smoke exposure, and group child care to the onset and duration of otitis media with effusion in the first two years of life. J Pediatr 1993; 123:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/23\">",
"      Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/24\">",
"      DiFranza JR, Lew RA. Morbidity and mortality in children associated with the use of tobacco products by other people. Pediatrics 1996; 97:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/25\">",
"      Bustamante J, Zhang SY, von Bernuth H, et al. From infectious diseases to primary immunodeficiencies. Immunol Allergy Clin North Am 2008; 28:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/26\">",
"      Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/27\">",
"      von Bernuth H, Ku CL, Rodriguez-Gallego C, et al. A fast procedure for the detection of defects in Toll-like receptor signaling. Pediatrics 2006; 118:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/28\">",
"      Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008; 28 Suppl 1:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/29\">",
"      Szczawinska-Poplonyk A, Gerreth K, Breborowicz A, Borysewicz-Lewicka M. Oral manifestations of primary immune deficiencies in children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/30\">",
"      Hausser C, Virelizier JL, Buriot D, Griscelli C. Common variable hypogammaglobulinemia in children. Clinical and immunologic observations in 30 patients. Am J Dis Child 1983; 137:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/31\">",
"      Mason EO Jr, Wald ER, Tan TQ, et al. Recurrent systemic pneumococcal disease in children. Pediatr Infect Dis J 2007; 26:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/32\">",
"      Buckley RH. The multiple causes of human SCID. J Clin Invest 2004; 114:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/33\">",
"      McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1987; 9:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/34\">",
"      Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med 1977; 296:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/35\">",
"      Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/36\">",
"      Fischer A. Primary T-lymphocyte immunodeficiencies. Clin Rev Allergy Immunol 2001; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/37\">",
"      Fischer A. Severe combined immunodeficiencies (SCID). Clin Exp Immunol 2000; 122:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/38\">",
"      Ellison RT 3rd, Kohler PF, Curd JG, et al. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningocococcal disease. N Engl J Med 1983; 308:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/39\">",
"      Lim D, Gewurz A, Lint TF, et al. Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J Pediatr 1976; 89:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/40\">",
"      Zoppi M, Weiss M, Nydegger UE, et al. Recurrent meningitis in a patient with congenital deficiency of the C9 component of complement. First case of C9 deficiency in Europe. Arch Intern Med 1990; 150:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/41\">",
"      Potter PC, Frasch CE, van der Sande WJ, et al. Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement. J Infect Dis 1990; 161:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/42\">",
"      Lehman HK, Ballow M. Immune deficiency disorders with autoimmunity and abnormalities in immune regulation-monogenic autoimmune diseases. Clin Rev Allergy Immunol 2008; 34:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/43\">",
"      Paul ME, Shearer WT. The child who has recurrent infection. Immunol Allergy Clin North Am 1999; 19:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/44\">",
"      Hernandez-Trujillo VP, Fleisher TA. Interpretation of flow cytometry in primary immunodeficiency disorders. Ann Allergy Asthma Immunol 2008; 100:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/47/30458/abstract/45\">",
"      Lehman HK, Hernandez-Trujillo VP, Ballow M. The use of commercially available genetic tests in immunodeficiency disorders. Ann Allergy Asthma Immunol 2008; 101:212.",
"     </a>",
"    </li>",
"    <li>",
"     Buckley RH (Ed). Diagnostic and clinical care guidelines for primary immunodeficiency diseases: Immune Deficiency Foundation 2006. www.primaryimmune.org (Accessed on August 28, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5949 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30458=[""].join("\n");
var outline_f29_47_30458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5015545\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5015731\">",
"      Clinical features suggestive of a primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAJOR CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The \"normal\" child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The child with atopic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The child with chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The child with an immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5016183\">",
"      - Primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Secondary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Birth history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Growth and development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunization history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other illnesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Social history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Infection history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Age of onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sites of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical patterns suggestive of immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Initial tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - General screening tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3920595\">",
"      - Immunoglobulin levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Infection evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3920576\">",
"      Intermediate tests for immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Antibody titers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Complement activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Lymphocyte subset analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Vaccine challenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - IgG subset determinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - HIV testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Delayed cutaneous hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Lymphoproliferative assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Phagocytic oxidative responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Leukocyte adhesion defect testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Complement component",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Confirmatory diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MANAGEMENT OF THE CHILD WITH RECURRENT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5949|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/56/29571\" title=\"diagnostic image 1\">",
"      Chest x-rays with and without thymic shadows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/36/15951\" title=\"diagnostic image 2\">",
"      Hypoplasia lymphoid tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5949|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/31/8703\" title=\"figure 1\">",
"      Rela incid immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5949|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/31/42495\" title=\"picture 1\">",
"      Hyperplasia lymphoid tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/4/3149\" title=\"table 1\">",
"      Clinical features of immunodeficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/6/35949\" title=\"table 2\">",
"      Vaccination in primary immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7992?source=related_link\">",
"      Cartilage-hair hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35525?source=related_link\">",
"      Diagnostic testing for HIV infection in infants and children younger than 18 months",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=related_link\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38233?source=related_link\">",
"      Poor weight gain in children older than two years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=related_link\">",
"      Suspected heart disease in infants and children: Criteria for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40295?source=related_link\">",
"      Syndromic immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=related_link\">",
"      Virus-induced wheezing and asthma: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_47_30459="Evaluation fever after OLT";
var content_f29_47_30459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of fever after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        History and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Laboratory testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complete blood count, liver enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinalysis, urine culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sputum Gram stain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blood cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Radiologic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest X-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional studies based upon clinical setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMV rapid antigen or CMV quantitative PCR testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest CT and/or bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound of liver +/- cholangiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head CT and lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal imaging: CT with contrast, magnetic resonance imaging (MRCP)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; CMV: cytomegalovirus; MRCP: magnetic resonance cholangiopancreatography; PCR: polymerase chain reaction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30459=[""].join("\n");
var outline_f29_47_30459=null;
var title_f29_47_30460="Lead and CKD";
var content_f29_47_30460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Studies evaluating the role of lead in CKD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Reference",
"      </td>",
"      <td class=\"subtitle1\">",
"       N",
"      </td>",
"      <td class=\"subtitle1\">",
"       Baseline mean (SD) blood lead (microgram/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Baseline mean (SD) chelatable lead (microgram/72 hours)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Baseline mean (SD) eGFR (mL/min/1.73 m2)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Follow-up (years)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Decline in eGFR per 1 SD higher lead dose at baseline per year",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       [1]",
"      </td>",
"      <td>",
"       202",
"      </td>",
"      <td>",
"       5.3 (2.9)",
"      </td>",
"      <td>",
"       104.5 (106.3)",
"      </td>",
"      <td>",
"       41.6 (14.4)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       0.16",
"      </td>",
"      <td>",
"       Largest study to date",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       [2]",
"      </td>",
"      <td>",
"       121",
"      </td>",
"      <td>",
"       4.2 (2.2)",
"      </td>",
"      <td>",
"       99.1 (83.4)",
"      </td>",
"      <td>",
"       36.0 (9.8)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       <p>",
"        2.7 (chelatable)",
"       </p>",
"       <p>",
"        2.2 (blood lead)",
"       </p>",
"      </td>",
"      <td>",
"       Longest follow-up; 1 microgram/dL higher blood lead, at baseline, associated with 4.0 mL/min/1.73 m2 reduction in eGFR over 4 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       [3]",
"      </td>",
"      <td>",
"       87",
"      </td>",
"      <td>",
"       6.5 (3.4)",
"      </td>",
"      <td>",
"       108.5 (53.8)",
"      </td>",
"      <td>",
"       35.1 (9.0)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       3.87",
"      </td>",
"      <td>",
"       Type II diabetics with nephropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       [4]",
"      </td>",
"      <td>",
"       108",
"      </td>",
"      <td>",
"       2.9 (1.4)*",
"      </td>",
"      <td>",
"       40.2 (21.2) (all &lt;80)",
"      </td>",
"      <td>",
"       47.6 (9.8)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1.1",
"      </td>",
"      <td>",
"       Lowest lead exposed CKD patients",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Notably, mean blood lead level in this study was below that observed in a recent large general population study of 50-70 year olds in Baltimore, MD",
"     <sup>",
"      [5]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Lin, JL, Lin-Tan, DT, Hsu, KH, Yu, CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348:277.",
"      <br>",
"       2. Yu, CC, Lin, JL, Lin-Tan, DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol 2004; 15:1016.",
"       <br>",
"        3. Lin, JL, Lin-Tan, DT, Yu, CC, et al. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int 2006; 69:2049.",
"        <br>",
"         4. Lin, JL, Lin-Tan, DT, Li, YJ, et al. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med 2006; 119:707.",
"         <br>",
"          5. Martin, D, Glass, TA, Bandeen-Roche, K, et al. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 2006; 163:467.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30460=[""].join("\n");
var outline_f29_47_30460=null;
var title_f29_47_30461="Contents: Nutrition and diet";
var content_f29_47_30461=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Nutrition and diet",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Nutrition and diet",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/5/17498\">",
"           Benefits and risks of caffeine and caffeinated beverages",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/40/23175\">",
"           Dietary and nutritional assessment in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36330\">",
"           Fish oil and marine omega-3 fatty acids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31641\">",
"           Healthy diet in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28650\">",
"           Overview of water-soluble vitamins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/46/36586\">",
"           Vitamin supplementation in disease prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E01CC5E385-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f29_47_30461=[""].join("\n");
var outline_f29_47_30461=null;
var title_f29_47_30462="Ages foster care";
var content_f29_47_30462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ages of children in foster care",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 416px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: US Department of Health and Human Services. The AFCARS Report (Preliminary FY 2010 estimates).",
"     <a href=\"file://www.acf.hhs.gov/programs/cb/stats_research/afcars/tar/report18.pdf\" target=\"_blank\">",
"      www.acf.hhs.gov/programs/cb/stats_research/afcars/tar/report18.pdf",
"     </a>",
"     (Accessed on January 25, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30462=[""].join("\n");
var outline_f29_47_30462=null;
var title_f29_47_30463="Bipolar unipolar electrograms";
var content_f29_47_30463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Bipolar and unipolar electrograms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper tracing shows a bipolar electrogram and the lower tracing shows overlapping simultaneous unipolar recordings from the two poles comprising the bipole. The solid line is from unipolar #1 and the dashed line is from the inverted tracing from unipolar #2; unipolar #2 is inverted to correspond to the recording vector it serves in the bipolar recording. In the unipolar recordings, there is a gradual upsloping and downsloping of the potential, which is generated by far-field activation. The shaded area between the two unipolar tracings represents the portion of the signal subtracted out in the bipolar recording.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_47_30463=[""].join("\n");
var outline_f29_47_30463=null;
